Platelet activation and platelet-monocyte aggregate formation by the atherosclerotic plaque lipid lysophosphatidic acid by Haserück, Nadine
Aus dem Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten 
der Ludwig-Maximilians-Universität München 
Direktor: Prof. Dr. med. P. C. Weber 
 
 
 
 
 
Platelet activation and platelet- monocyte aggregate 
formation induced by the atherosclerotic plaque lipid 
lysophosphatidic acid 
 
 
 
 
Dissertation  
zum Erwerb des Doktorgrades der Medizin 
an der Medizinischen Fakultät der  
Ludwig-Maximilians-Universität zu München 
 
 
 
vorgelegt von  
Nadine Haserück 
 
 
aus  
München 
 
2007 
 
 
Mit Genehmigung der Medizinischen Fakultät 
der Universität München 
 
 
 
 
 
 
1. Berichterstatter:      Prof. Dr. Wolfgang Siess 
2. Berichterstatter:     Priv. Doz. H.-Y. Sohn 
 
Mitberichterstatter:     Priv. Doz. Dr. M. Weis  
        Prof. Dr. B. Walzog 
 
Dekan:        Prof. Dr. med. D. Reinhardt 
 
Tag der mündlichen Prüfung:   11.10.2007 
 
 
 
 
 
 
 
 
Table of contents i
Table of contents 
Table of contents ...............................................................................................................................i 
Abbreviations ..................................................................................................................................iv 
1. Introduction ..................................................................................................................................1 
2. State of Research ..........................................................................................................................2 
2.1. General mechanism of platelet activation and arterial thrombus formation .........................2 
2.2. Arterial thrombus formation induced by atherosclerotic plaques .........................................3 
2.3. Lysophosphatidic acid...........................................................................................................4 
2.3.1. LPA in plasma and serum ..............................................................................................5 
2.3.2. LPA- Formation .............................................................................................................6 
2.3.3. LPA degradation.............................................................................................................8 
2.3.4. Transport- and binding- proteins of LPA: albumin, intracellularly  fatty acid binding 
proteins, and gelsolin................................................................................................................9 
2.3.5. Platelet shape change and aggregation induced by LPA..............................................11 
2.3.6. LPA-receptors ..............................................................................................................12 
2.4. Platelet-monocyte interaction..............................................................................................13 
2.4.1. LPA-induced platelet-monocyte activation..................................................................13 
2.4.2. Mechanisms of platelet-monocyte interaction .............................................................14 
3. Key Questions addressed............................................................................................................15 
4. Materials and methods................................................................................................................16 
4.1. Materials..............................................................................................................................16 
4.2. Buffers .................................................................................................................................18 
4.3. Methods ...............................................................................................................................18 
4.3.1. Preparation of LPA.......................................................................................................18 
4.3.2. Preparation and Incubation of other agonists and antagonists .....................................19 
4.3.3. Blood Preparation.........................................................................................................19 
4.3.4. Preparation of Platelet-Rich-Plasma (PRP)..................................................................19 
4.3.5. Preparation of washed platelets....................................................................................20 
 
Table of contents ii
4.3.6. Measuring shape change and aggregation in washed platelets and platelet- rich- 
plasma (PRP)..........................................................................................................................22 
4.3.7. Aggregation in blood....................................................................................................22 
4.3.8. Measuring cAMP levels in platelets.............................................................................22 
4.3.9. Quantifying platelet aggregates and platelet-monocyte- aggregates (PMA) and P-
selectin expression..................................................................................................................24 
5. Results ........................................................................................................................................26 
5.1. Response of washed platelets to LPA: Comparison of different platelet isolation 
procedures ..................................................................................................................................26 
5.1.1. LPA only induced shape change of platelets isolated according to method 1 and 
method 2 .................................................................................................................................26 
5.1.2. LPA induced aggregation of platelets isolated according to method 3 and method 4 .27 
5.2. LPA-induced shape change in washed platelets, PRP, and whole blood ...........................29 
5.2.1. Shape change induced by LPA in washed platelets and in the presence of albumin or 
plasma.....................................................................................................................................29 
5.2.2. Shape change induced by LPA in washed platelets in the presence of gelsolin ..........31 
5.2.3. Shape change induced by LPA of washed platelets, PRP and blood is mediated by 
Rho-kinase activation – but independent of ADP receptors P2Y1 and P2Y12 .......................32 
5.2.4. Comparison of 1-acyl-LPA (16:0) and 1-alkyl-LPA (16:0)- induced shape change in 
PRP and in whole blood .........................................................................................................32 
5.3. PA -induced aggregation in PRP and whole blood ............................................................33 
5.3.1. LPA induced platelet aggregation and ATP secretion in PRP: donor dependent 
variations ................................................................................................................................33 
5.3.2. Low concentrations of LPA induced aggregation in whole blood..............................35 
5.3.3. 1-acyl-LPA (16:0) versus 1-alkyl-LPA (16:0) induced aggregation in whole blood..37 
5.3.4. LPA- induced platelet aggregation in whole blood is independent of the type of 
anticoagulant ..........................................................................................................................38 
5.4. Mechanisms of LPA-induced platelet aggregation .............................................................41 
5.4.1. LPA-induced platelet aggregation in washed platelets and in PRP is partly mediated 
by secreted ADP.....................................................................................................................41 
5.4.2. Mediators of LPA -induced aggregation in whole blood .............................................48 
 
Table of contents iii
5.5. LPA synergizes with different platelet stimuli in inducing platelet aggregation in washed 
platelets and whole blood ...........................................................................................................51 
5.6. Role of LPA produced by platelets in thrombin- or collagen- stimulated platelet 
aggregation .................................................................................................................................55 
5.7. LPA- induced platelet-monocyte interaction ......................................................................56 
5.7.1. Mechanism of LPA-induced platelet-monocyte aggregate formation .........................57 
5.7.2. Specific desensitization of the LPA-receptor mediated platelet- monocyte aggregate 
formation in whole blood .......................................................................................................60 
6. Discussion ..................................................................................................................................61 
6.1. LPA induced shape change in washed platelets, PRP, and whole blood ............................61 
6.2. Platelet aggregation in washed platelets, PRP, and whole blood........................................62 
6.2.1.Difference in aggregation using different isolation procedures of washed platelets ....62 
6.2.2. Aggregation in PRP and whole blood ..........................................................................63 
6.2.3. Activation by different LPA species ............................................................................64 
6.2.4. LPA-induced aggregation in blood and PRP- independence of the anticoagulant ......65 
6.2.5. Synegistic interaction of LPA with serotonin, epinephrine and ADP..........................66 
6.2.6. LPA is not a positive feed-back mediator of platelet activation ..................................67 
6.2.7. Perspective: Preventing LPA-induced platelet aggregation.........................................68 
6.3. LPA- induced platelet-monocyte adhesion in whole blood ................................................68 
6.3.1. Perspective: Prevention of LPA-induced platelet-monocyte aggregate formation ......70 
7. Summary ....................................................................................................................................71 
8. Zusammenfassung ......................................................................................................................73 
9. Reference List.............................................................................................................................75 
Acknowledgements ........................................................................................................................88 
List of publications.........................................................................................................................89 
Curriculum vitae.............................................................................................................................90 
 
 
 
Abbreviations iv
Abbreviations 
 
µM  micomolar 
- A - 
A3P5P  P2Y1-receptor antagonist 
ADP  adenosine- diphosphate 
AR-C69931 P2Y12- receptor antagonist 
ASS  acetyl- salicic acid 
ATP  adenosine- triphosphate 
 
- B - 
 
BSA  bovine serum albumin 
 
- C - 
 
CD cluster or differentiation, a cell surface marker, i.e. CD41 
COX-1 cyclooxygenase 1  
 
- D - 
 
DGPP  diacylglycerolpyrophosphate 
DMSO  dimethyl-sulfoxide 
 
- E - 
 
EC effective concentration 
EDG endothelial differentiation gene (former description for LPA- /S1P- receptors) 
EDTA ethylene- diamine- tetra- acetic acid 
 
Abbreviations v
- G - 
 
GP membrane glycoprotein, i.e. GPIIb-IIIa = integrin αIIbβ3
 
- I - 
 
IL-6  interleukin 6 
 
- L - 
 
LPA  lysophosphatic acid 
LPAAT LPA-acetyltransferase 
LPC  lysophosphatidylcholine 
LPP lipidphosphate- phosphohydrolase 
Lyso-PLD lysophospholipase D (formerly autotaxin) 
 
- M - 
 
M  molar 
MAG  monoacylglycerol 
mM  millimolar 
MMP matrix-metalloproteinase 
MRS2179 P2Y1- receptor antagonist 
 
- N - 
 
NATyrPA N-acyl-Tyrosine- phosphoic acid  
NASerPA N-acyl-Serine- phosphoric acid  
NFκB a transcriptionsfactor 
 
Abbreviations vi
- O - 
 
Ox-LDL oxidized- low-density- lipoprotein 
 
- P - 
 
P2Y1/12 ADP-receptors  
PA  phosphatidic acid 
PAF  platelet activating factor  
PBS  phosphate buffered saline 
PC  phosphatidylcholine 
PCR  polymerase-chain -reaction 
PDGF  platelet derived growth factor 
PLA  phospholipase A 
PLD  phospholipase D 
PPP platelet poor plasma 
PPAR peroxisome proliferator-activated receptor (a transcription factor) 
PRP platelet rich plasma 
PS phosphatidylserine 
 
 
- R - 
 
RGDS  Arg-Gly-Asp-Ser (a fibrinogen receptor blocking peptide) 
 
- S - 
 
S1P  sphingosine-1-phosphate 
SD  standard deviation  
 
Abbreviations vii
- T - 
 
TF  tissue factor 
TNF  tumor necrosis factor 
 
- U - 
 
U46619 a thromboxane receptor agonist 
 
- V - 
 
VCAM vascular cell adhesion molecule 
vWF von Willebrand factor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 1
1. Introduction 
 
Platelets are anucleated blood cells that originate from the bone marrow by fragmentation of 
megakaryocytes (Hartwig and Italiano, 2003). Under conditions of regular blood flow platelets 
circulate freely at a concentration of 150 – 300 x 10 9/ l and they do not adhere to the vascular 
wall. In the event of vascular injury platelets adhere to the site of the lesion where they contribute 
to primary haemostasis and thus arrest haemorrhage after vascular tissue trauma. Acute vascular 
injury marks the physiological trigger for platelet function.  
In atherosclerosis, plaque rupture leads to a similar sequence of platelet activation. Whether 
through acute injury or chronic lesions in atherosclerosis, platelets act in the same way changing 
their shape, aggregating and thus leading to the formation of a platelet- and fibrin-rich 
intravascular thrombus. Thus “erroneous” activation of intravascular haemostasis is of paramount 
importance in the pathogenesis of acute thrombotic intravascular occlusion in atherosclerosis. It 
is this basic event which precipitates acute ischemic syndromes such as unstable angina, 
myocardial infarction, peripheral arterial occlusion and stroke. The mechanism by which platelet 
activation is triggered after plaque rupture is of vital importance. Within atherosclerotic arteries 
one possible culprit for intravascular platelet activation are oxidized lipids being suddenly 
exposed to circulating platelets upon plaque rupture. 
The following work will focus on one of those specific platelet- activating lipids, found after lipid 
oxidation, lysophosphatidic acid (LPA). Recently it has been recognized that LPA has thrombotic 
and atherogenic activities (Siess and Tigyi, 2004). Here we will focus on its platelet activating 
ability. LPA has been identified as a biologically active lipid in mildly oxidized LDL, human 
atherosclerotic lesions, and in the supernatant of activated platelets. It is known that LPA can 
cause platelet shape change and platelet aggregation. However, a systematic study concerning the 
mechanism of LPA- induced aggregation is missing. Moreover, it is unknown whether LPA 
induces platelet aggregation in whole blood.  
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2. State of Research 
2.1. General mechanism of platelet activation and arterial thrombus 
formation 
Under physiological conditions the main trigger for the formation of a haemostatic thrombus is 
the loss of the endothelial cell integrity, which causes platelets to come into contact with 
subendothelial matrix components mediating the initial adherence of platelets.  Subendothelial 
components exposed locally (like collagen) bind circulating von Willebrand factor (vWF), which 
causes platelet adhesion, sustains platelet activation and may cause platelet aggregation (Savage 
et al., 1996). Circulating plasma factors and molecules released from platelets can cause positive 
feedback loops of platelet activation. Some of these plasma factors are: epinephrine, increased 
under conditions of stress, thrombin, formed by the coagulation system, thromboxane A2 (TXA2), 
ADP, and serotonin, released by the activation of platelets (Siess, 1989). 
Upon activation platelets undergo several closely intertwined phases: shape, adhesion, secretion, 
and aggregation. Non- activated circulating platelets are mostly discoid in shape. However, 
depending on the stage of activation, other forms of platelets, for example spheroid forms, are 
circulating in plasma. Platelets can undergo shape change which involves platelets to become 
spheroid and form protuberances, which can be motile, extend and retract. These extensions are 
called pseudopods and can facilitate the adherence of platelets to injured endothelial surfaces and 
to each other.  
Once adherent to a surface some of the platelets may flatten laterally extending their cell body 
between the pseudopods (=spreading). This process allows a platelet monolayer of activated 
platelets to firmly attach and seal an endothelial lesion.  
Independent of whether activated platelets adhere and spread or whether they aggregate, they 
may secrete the contents of their dense granules (ADP and serotonin) and α-granules, or release 
thromboxane A2 (TXA2). These factors can amplify platelet activation leading to further platelet 
secretion and aggregation.  
The exposure of an active fibrinogen receptor (glycoprotein GPIIb-IIIa complex, integrin αIIbβ3) 
is required for aggregation (Plow and Ginsberg, 1989). About 80 000 copies of the fibrinogen 
receptor exist on the surface of unstimulated platelets and bind soluble fibrinogen in its activated 
form leading to the formation of fibrinogen bridges between platelets. (Phillips et al., 1988; Plow 
and Ginsberg, 1989). This process requires divalent cations (Ca2+, Mg2+) as a cofactor. Distinct 
amino acid sequences, like RGD or KQAGDV, that are present in the fibrinogen molecule 
sequence, mediate the ligand receptor interaction and bind to specific extracellular regions of the 
integrin αIIbβ3. By inhibition of these amino acid sequences aggregation can be completely 
abolished (Phillips et al., 1988; Plow and Ginsberg, 1989). The integrin αIIbβ3 can also bind other 
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plasma constituents like von Willebrand factor (vWF), and fibronectin which leads to further 
recruitment of platelets (Ruggeri, 2002). 
There are two types of aggregation: a transient, reversible form and an irreversible form. With the 
reversible form agonists stimulate, within seconds, the initial binding of adhesive ligands, like 
fibrinogen to the integrin αIIbβ3. This initial binding is reversible. With further platelet activation 
through TXA2 generation and secretion of ADP and diverse proteins from α-granules (such as 
thrombospondin) reversible aggregation becomes irreversible (Gawaz, 2001). With irreversible 
aggregation the activation of the αIIbβ3 integrin leads to the immobilization of soluble fibrinogen, 
vWF, and fibronectin onto the surface of adherent platelets. Combined with the activation of the 
coagulation system on the surface of activated platelets a stable and permanent thrombotic 
occlusion occurs. 
2.2. Arterial thrombus formation induced by atherosclerotic plaques 
Under pathophysiological conditions haemostatic factors play a crucial role in generating a 
thrombotic plug at the site of vascular damage. Studies have revealed that there are several stages 
in atherosclerotic plaque formation. A lesion is initiated by lipid accumulation in the intima and 
inflammatory leukocyte recruitment by activated endothelial cells. Macrophages accumulate 
oxidized low-density lipoprotein (oxLDL) and become lipid rich foam cells. Migration of smooth 
muscle cells from the media to the intima and their proliferation leads to the synthesis of 
extracellular matrix. Lesion progression is characterized by degradation of the matrix and by 
weakening of the fibrous cap.  
Plaque damage can occur by apoptosis of endothelial cells leading to erosion or rupture. In all 
cases thrombogenic plaque material is exposed to circulating blood. Some of these thrombogenic 
factors are tissue factor, which stimulates the coagulation system, and numerous molecules which 
activate platelets, such as subendothelial collagen, vWF, cholesterol sulfate, oxidized 
phosphatidyl choline and LPA (Katsuda and Kaji, 2003) ((Abi-Younes et al., 2000; Barnes and 
Farndale, 1999; De Meyer et al., 1999; Libby et al., 2002; Merten et al., 2001; Rajavashisth et al., 
1999; Siess et al., 1999; Weidtmann et al., 1995).  
Tissue factor (TF) is a transmembrane glycoprotein that serves as one of the primary initiators of 
blood coagulation. TF is present on fibroblasts, smooth muscle cells (especially those in 
atherosclerotic plaques), and under pathophysiological conditions expressed on endothelial cells 
and circulating monocytes (Camerer et al., 1996). TF binds to FVIIa of the coagulation cascade 
and enhances the FVIIa catalytic activity generating FIXa and FXa which leads to thrombin 
generation, subsequent platelet activation, and fibrin synthesis.  
In response to various chemical (TNF, IL-1, MCP-1, or IL6) and mechanical stimuli TF activity 
is up-regulated by monocytes and endothelial cells (Lorenzet et al., 1998). It is known that the 
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interaction of monocytes with platelets facilitates TF expression on monocytes (Celi et al., 1994). 
In turn, TF expression on monocytes facilitates the interaction of monocytes with activated 
platelets via binding of P-selectin (Shebuski et al., 2002). The end result of the increased 
expression of TF on monocytes is the acceleration of the rate and extent of fibrin formation and 
deposition in a thrombus or plaque.  
Upon lesion of the vessel wall, plaque rupture or erosion, platelet adhesion to collagen under 
arterial flow conditions (high shear rate) is critically dependent on the interaction of activated 
vWF with platelet glycoprotein GPIb (vWF-Receptor). Platelet glycoprotein Ib receptor binding 
of circulating vWF leads to a conformational change of vWF, which then binds to exposed 
collagen, namely type I, III, or VI (Dent et al., 1990; Ruggeri, 2002; Zimmerman et al., 1986). 
Subendothelial collagen interacts with two membrane glycoproteins in platelets, integrinα2β1 
(GPIa-IIa) and GPVI. Both, integrinα2β1 and GPVI, mediate platelet adhesion and generation of 
intracellular signals for platelet activation. Both collagen receptors can stimulate the cytosolic 
tyrosine kinase Syk, which phosphorylates and thereby activates phospholipase Cγ2 leading to an 
increase in cytosolic Ca2+ via production of inositol-1,4,5-trisphosphate (Keely and Parise, 1996; 
Tokumura et al., 1987). The activation of platelets by collagen is carefully balanced out by the 
platelet-endothelial cell adhesion molecule 1 (PECAM-1, CD 31), which serves as an inhibitory 
receptor (Patil et al., 2001). 
Other substances described in atherosclerotic plaques which can directly activate platelets are 
oxidized phosphatidylcholine, cholesterol sulfate, PAF and LPA. PAF is a powerful mediator of 
inflammation apart from directly activating platelets and may contribute to plaque formation 
(Brocheriou et al., 2000; Lupia et al., 2003; Mueller et al., 1995). 
Here we will focus on LPA, which has been shown to mediate platelet activation by the plaque- 
lipid rich core (Rother et al., 2003; Siess et al., 1999). Important in the context of this work is the 
accumulation of LPA in the intima of atherosclerotic lesions (Rother et al., 2003; Siess et al., 
1999). 
2.3. Lysophosphatidic acid 
LPA activates platelets directly. It has been shown to be formed during mild oxidation of low-
density lipoprotein (LDL) and to accumulate in the lipid rich core of human atherosclerotic 
plaques. LPA receptor antagonists can abrogate the platelet activating effects of not only LPA, 
but also mox-LDL and plaque core-lipids (Rother et al., 2003) (Siess et al., 1999). LPA binds to 
three or more specific plasma membrane receptors and elicits a wide range of biological effects 
including platelet activation, the stimulation of cell proliferation, migration, smooth muscle cell 
contraction, apoptosis, as well as the promotion of cell survival (Mills and Moolenaar, 2003; 
Tigyi and Parrill, 2003). These biological effects combined provide evidence that LPA might also 
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initiate and perpetuate pathophysiological processes such as inflammation and atherogenesis 
(Siess, 2002). 
2.3.1. LPA in plasma and serum 
LPA present in plasma ranges in a concentration from 100-500 nM (Baker et al., 2002; Bjerve et 
al., 1974; Sano et al., 2002), whereas the serum concentration of LPA is in the 1-10 μM range 
(Baker et al., 2001; Sano et al., 2002; Saulnier-Blache et al., 2000). This difference in 
concentration implies that LPA is formed during blood coagulation and platelet activation 
probably through the interaction of enzymes released from activated platelets and plasma 
phospholipids. 
 
LPA structure 
The basic LPA structure consists of a glycerol backbone, a phosphate group and a fatty acid 
chain. The variability of the LPA species lies in the length and saturation of the fatty acid chain, 
and in the link of the fatty acid chain (ester or ether link) at position C1. Plasma LPA is 
composed of varying fatty acid chains, C18:0, C16:0, C18:1 and C20:4 (Baker et al., 2001; Pages 
et al., 2001). 
In this dissertation acyl-LPA (16:0), acyl-LPA (18:1) and alkyl-LPA (16:0) were used. For 
illustration see the Figure below. 
 
 
Fig 2.1 
LPA structures for 1-acyl LPA (18:1) (A) and 1-alkyl LPA (16:0) (B) 
LPA is the simplest phospholipid and consists of a glycerol backbone with a hydroxyl group at position sn-2 (or sn-
1) attached to a phosphate group at position sn-3 and a fatty acid chain at position sn-1 (or sn-2).  
Structure (A) shows oleoyl-Lysophosphatidic acid also called acyl-LPA (18:1), structure (B) shows mono-(16:0)-
alkyl-glycerol-phosphate or alkyl-LPA (16:0), 1-acyl LPA has a double bond oxygen at C1 in contrast to 1-alkyl 
LPA. 
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2.3.2. LPA- Formation  
A critical concentration of LPA has to be produced and transported to the extracellular medium, 
since LPA interacts with membrane receptors. LPA can be synthesized by a number of different 
cell types, including platelets (Moolenaar, 1995). 
Here we will focus on LPA being formed by a number of different mechanisms, as an 
intermediate product in the intracellular lipid synthetic pathways or produced in a stimulus-
coupled manner.  
 
Intracellular LPA as a precursor in glycerolipid synthesis 
In the chain of reactions in glycerolipid synthesis LPA formation can be catalyzed by the enzyme, 
glycerophosphate acyltransferase (GPAT), located in both endoplasmatic reticulum and 
mitochondria. GPAT acylates glycerol-3 phosphate into LPA as an intermediate product before 
LPA is then acylated by monoacylglycerolphosphate acyltransferase (MGAT) into phosphatidic 
acid (PA), the precursor of all glycerolipids (Haldar and Vancura, 1992).  
An alternative pathway is the reduction of acyl dihydroxyacetone phosphate (acyl DHAP) in 
peroxysomes contributing to LPA formation in pancreatic islets exposed to high glucose 
concentrations (Dunlop and Larkins, 1985). 
Further LPA can be synthesized by the action of monoacylgycerol kinase (MAG-kinase) on 
monoacylglycerol, as an important precursor of phosphatidylinositol synthesis(Simpson et al., 
1991). MAG kinase has also been proposed to be involved in the formation of arachidonoyl-LPA 
in platelets (Gerrard and Robinson, 1989). However, whether LPA, produced during glycerolipid 
synthesis, can accumulate and contribute to the extracellular release of phospholipids is not yet 
resolved.  
 
Extracellular LPA Generation by phospholipid hydrolysis 
Hydrolysis of fatty acids at the sn-1 position by phospholipase A1 (PLA1) or at the sn-2 position 
by phospholipase A2 (PLA2) generates LPA from PA. Platelets and to a smaller degree red blood 
cells, have been identified as sources of LPA in blood (Eichholtz et al., 1993). PA was found to 
be rapidly generated in thombin-stimulated platelets and could subsequently be converted to LPA 
via PLA enzymes (Lapetina et al., 1981a, b). LPA generated through this mechanism appears 
within 15 min following thrombin stimulation and constitutes only a minor portions, estimated 
10%, of LPA detected in serum (Aoki et al., 2002; Gaits et al., 1997; Sano et al., 2002). 
A larger proportion of LPA has been shown to be produced in plasma by platelets releasing PLA1 
and PLA2 that generate a de novo pool of lysophospholipids primarily lysophosphatidylcholine 
(LPC) from Phosphaditylcholine (PC) in plasma and membrane phospholipids (Sano et al., 
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2002). LPC can then be further metabolized by the enzyme lysophospholipase D (lyso-PLD) 
identical to the tumor cell motility stimulating protein known as autotaxin (Tokumura et al., 
2002) (See Fig 2.2 below). Autotaxin belongs to the family nucleotide pyrophosphatase/ 
phosphodiesterases and promotes tumor cell motility, progression, metastasis, and angiogenesis 
via a pertussis toxin-sensitive mechanism (Lee et al., 2002b; Nam et al., 2001; Stracke et al., 
1997). These activities have also been described for LPA (Imamura et al., 1993; Imamura et al., 
1996). LPA production due to lyso-PLD activity in human whole blood ex vivo has been 
described as fairly rapidly and amounts to about 1.2μM within 1 h (starting from approximately 
130 nM) (Baker et al., 2001). Sano et al have used activated plasma and showed a 20-fold 
increase within the first hour (Sano et al., 2002). 
However, this increase is not due to an increase in Lyso-PLD activity (Aoki et al., 2002; Sano et 
al., 2002), but has been proposed to be caused by PLA1, PLA2, capable of not only generating 
lysophosphatidylcholine (LPC), but also lysophosphatidylserine (LPS), and 
lysophosphatidylethanolamine (LPE) from plasma PC, PS, and PE. An important source of LPC, 
being the most abundant lysophospholipid (125-150μM) in plasma, is the enzyme lecithin-
cholesterol acyltransferase (LCAT) (Croset et al., 2000; Tokumura et al., 1999). 
 
 
Fig 2.2 
Schematic Model of LPA formation 
PA = phosphatidic acid, sPLA1/2 = secretory phospholipase A1/2  LysoPLD= lysophospholipase D 
Phosphatidylcholine and Phosphatidyl ehanolamine are located in plasma and on the outside cell membrane. 
In addition, a secretory or type II PLA2 (sPLA2) with slightly different activity than PLA2, has 
been implicated in LPA production from microvesicles shed by inflammatory cells (Gerrard and 
Robinson, 1989). sPLA2 hydrolyzes phospholipids of lipoproteins and microvesicle membranes 
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that have altered membrane asymmetry that leads to PA accumulation in the outer leaflet of the 
plasma membrane (Eckey et al., 2004; Fourcade et al., 1995; Hurt-Camejo et al., 2001; Snitko et 
al., 1997). Especially aminophospholipids like phosphatidylethanolamine and phosphatidylserine 
are hydrolyzed by sPLA2 generating the corresponding lysophospholipid substrate for lyso-
phospholipase D cleavage (Fig 2.2) (Gaits et al., 1997).  
 
LPA contained in atherosclerotic plaques can be formed by mild oxidation of LDL 
Mild oxidation of LDL leads to a large increase of its LPA content as compared to native LDL. 
LPA exposed on mildly oxidized LDL has been shown to activate platelets and endothelial cells 
(Siess et al., 1999). Mild oxidation of LDL, demarcating the early phase of atherosclerotic lesion 
development, takes place mainly in the vascular intima, and is caused by superoxide anions 
formed by activated macrophages and endothelial cells (Holvoet and Collen, 1998; Ross, 1999; 
Sevanian et al., 1997). LPA also accumulates in the intima of human atherosclerotic lesions  and 
is predominantly present in the lipid rich core (Siess et al., 1999).  
LPA in atherosclerotic lesions may also be produced by the action of sPLA2  which is secreted 
upon cell stimulation with pro-inflammatory cytokines in human plaques (Hurt-Camejo et al., 
2001; Menschikowski et al., 2000).  
Additionally contributing to the LPA content in atherosclerotic plaques is the release of LPA by 
activated platelets, imparted in advanced lesions. 
2.3.3. LPA degradation  
Enzymatic removal of LPA results in functional inactivation of LPA and transformation into 
other bioactive lipid mediators. There are three major pathways of LPA degradation. The first 
step is phosphate removal to form monoacylglycerol by phosphatase or phosphohydrolizing 
enzymes. The second step is conversion to phosphatidic acid (PA) by acyltransferases. The third 
step is the removal of the sn-1 acyl chain to form glycerol phosphate by LPA-specific 
lysophospholipases. Important for our consideration is the first pathway involving a class of 
integral membrane enzymes, called lipid phosphate phosphatases (LPPs), since they most 
efficiently catalyze the dephosphorylation of LPA. 
LPP’s function as ecto- enzymes, degrading LPA into monoacylglycerol, an LPA-receptor 
inactive molecule. LPP’s are hydrophobic and localize to the plasma membrane and to 
intracellular membrane compartments. Studies published disagree widely on the mechanism and 
selectivity of the effect, but commonly conclude that overexpression of LPPs can attenuate 
cellular responses to LPA (Alderton et al., 2001; Hooks et al., 2001; Jasinska et al., 1999; Xu et 
al., 2000). Four isoforms of LPP’s have been cloned and subdivided according to their function. 
LPP1 and LPP3 are both present in platelets, whereby LPP1 shows a 16-fold higher activity and 
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is regulated by platelet agonists (Smyth et al., 2003). LPP1 accounts for the major LPP activity in 
human platelets and most efficiently catalyzes the dephosphorylation of LPA, followed by PA, 
sphingosine 1- phosphate (S1P) and ceramide 1- phosphate (C1P) (Roberts et al., 1998; 
Waggoner et al., 1996). Interestingly, when platelets were stimulated with thrombin-receptor 
activating protein (TRAP), ADP, or LPA platelet activation was accompanied by a relocalization 
of LPP1 and LPP3 to the platelet surface (Smyth et al., 2003). Moreover, antagonizing LPP1 by a 
receptor inactive phosphoinositide analog of LPA could enhance LPA- and ADP- induced 
platelet aggregation, shape change, Rho-activation, and even thrombin stimulated LPA 
production (Smyth et al., 2003). Thus LPP1 appears to be an important and rapid inhibitor of 
agonist-induced platelet activation.  
The second LPA degradation pathway involves the action of 1-acylglycerol 3–phosphate 
acyltransferase (AGPAT) enzymes, also called lysophosphatidic acid acyltransferases (LPAAT). 
These enzymes catalyze the formation of phosphatidic acid by transferring an acyl group from 
acyl-CoA to LPA. Proteins with LPAAT activity include a transmembrane family of enzymes 
and membrane associated proteins (Aguado and Campbell, 1998; Hannah et al., 1999; Leung, 
2001). They include five different members and are proposed to mediate the majority of activity 
within most cells (Leung, 2001). 
The third degradation pathway involves the hydrolysis of the fatty acyl group by the action of 
lysophopholipase A enzymes. The majority of these enzymes act on lysophosphatidyl choline 
(LPC) (Wang et al., 1999). However, an LPA specific lysophospholipase activity has been 
purified from rat brain (Thompson and Clark, 1994). 
2.3.4. Transport- and binding- proteins of LPA: albumin, intracellular  fatty 
acid binding proteins, and gelsolin 
LPA intra- and extra- cellular transport depends on the presence of binding proteins which 
facilitate solubility and transport of an amphiphilic molecule like LPA through a hydrophilic 
medium. Due to the hydrophobic character of the fatty acid chain, LPA has a high affinity to 
other proteins, most importantly, albumin.  
Albumin serves as an extracellular transport protein that binds LPA with an affinity constant, KD, 
of 360 nM and a stoichiometry of 3 moles LPA to 1 mole albumin (Thumser et al., 1994). In fact 
LPA released from activated platelets into the extracellular medium has only been able to be 
detected in the presence of albumin demonstrating the high affinity of albumin to LPA (Eichholtz 
et al., 1993; Tigyi et al., 1991). 
Albumin bound LPA is responsible for most heat stable and lysophospholipase-sensitive 
biological activities of serum (Ridley and Hall, 1992; Tigyi and Miledi, 1992). In addition LPA 
has been identified as the active molecule responsible for biological activity of serum albumin on 
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stimulation of Ca2+ efflux on Xenopus oocytes, actin stress fiber formation and cell proliferation 
(Ridley and Hall, 1992; Tigyi et al., 1991; Tigyi and Miledi, 1992). 
In a recent study Hama et al found that LPA receptor activation induced by added LPA can be 
inhibited by albumin present in serum. High concentrations of BSA (>5% w/v, physiological 
plasma concentration: 4% w/v) completely inhibited LPA-induced activation of the three LPA 
receptors, LPA3 being the most sensitive receptor (Hama et al., 2002).  
Intracellular fatty acid binding proteins (FABP’s) transport LPA from one organelle to the other 
with an affinity in the micromolar range. FABP’s aid in LPA metabolism when transporting LPA 
from mitochondria to microsomes where LPA is further acylated to phosphatidic acid (Vancura 
and Haldar, 1992). Additionally, FABP’s stimulate the enzyme glycerophosphate-acyltransferase 
which produces LPA from glycerolphosphate and fatty acid coenzyme A precursors (Jolly et al., 
1997). 
Another molecule, gelsolin, an approximately 85 kD/ Protein has been shown to be of potential 
intra- and extra- cellular importance. Extracellular gelsolin can bind to LPA and then either 
sequester it from or deliver it to its receptors. Intracellular gelsolin – a member of a family of 
actin binding proteins - binds and caps actin filaments and is thus involved in regulating the 
cytoskeleton architecture. Depending on the actin concentration gelsolin can either sever pre-
existing filaments, promote filament formation and cap fast growing actin filaments. Therefore, 
gelsolin can either promote or stop actin filament growth.  
The two forms of gelsolin, plasma and intracellular gelsolin have different structures due to 
alternative splicing (Kwiatkowski et al., 1986). Both forms contain a 730 amino acid core 
structure that is made up of six repeated domains. The six domains make up three distinct actin 
binding sites that have been localized within domains 1,2, and 4 (Kwiatkowski et al., 1986; Pope 
et al., 1995). A difference in structure and in activity between plasma and intracellular gelsolin 
has been shown (Huckriede et al., 1990; Wen et al., 1996).  
Structurally, plasma gelsolin has an intradomain disulfide bond within domain 2 which links 
Cys188 and Cys201, while in cytoplasmatic gelsolin all five cysteine residues are in their free thiol 
form (Wen et al., 1996) (See Fig. 2.3). 
Functionally, when comparing plasma, recombinant, and cytoplasmatic gelsolin by using 
microinjection, only plasma gelsolin was active on stress fiber networks, suggesting that 
functional differences exist on the activity within cells (Huckriede et al., 1990).  
Phosphoinositides, like PIP2 and Ca2+, regulate actin binding and severing activities of plasma 
gelsolin as measured by the intracellular effects in rat cardiomyocytes (Bucki et al., 2001). LPA 
binds to the same sites on gelsolin as PIP2  and was therefore proposed to regulate gelsolin 
activity by the same mechanism as PIP2 (Kwiatkowski, 1999; Meerschaert et al., 1998). 
Interestingly, the LPA/ PIP2 binding site lies within domain 2, coinciding with the site of the 
disulfide bond which distinguishes the cytoplasmatic gelsolin from plasma gelsolin.  
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Fig 2.3 
Schematic representation of domains of  plasma gelsolin and their functions. 
Amino acid positions are numbered as in human plasma gelsolin and segmental boundaries are based on the 
structural definitions defined by the gelsolin crystal. Actin, PIP2, and Ca2+-binding segments are shown.  Gelsolin 
domains are circled (Sun et al., 1999).  
Extracellular plasma gelsolin is present at concentrations of 100-250μg/ml (1.2- 2.9 μM) and 
binds LPA with high affinity close to that of LPA receptors (Kd 6 nM) and exceeding that of 
albumin (Kd 360 nM).  Extracellular gelsolin may function as a high affinity plasma carrier (Kd of 
32 nM), which protects a portion of circulating LPA from biodegradation and prevents LPA from 
binding to numerous possible low affinity proteins (Goetzl et al., 2000). Gelsolin concentrations 
of less than 10% of the plasma concentration were shown to increase LPA activity, whereas 20% 
or higher concentrations of those in plasma diminished biological effects of LPA in rat cardiac 
myocytes (Goetzl et al., 2000). 
In the context of this work, only a potential effect of gelsolin on the outside cell surface may play 
a role.  
2.3.5. Platelet shape change and aggregation induced by LPA 
The first report on platelet aggregation induced by LPA was done in 1979 by Schumacher et al., 
who discovered that in plasma, incubated at 36ºC for 18-24 hours, a factor developed, which on 
intravenous injection in cats evoked platelet aggregation followed by an increase in pulmonary 
vascular resistance (Schumacher et al., 1979). They also provided evidence that PA and LPA, are 
the active components causing aggregation of human and feline platelets. Of interest is that LPA 
was unable to induce aggregation in dogs, rabbits, pigs, and rats (Mauco et al., 1978; Schumacher 
et al., 1979). 
LPA (Oleoyl-LPA or 18:1) is a potent activator of platelets and induces shape change of human 
isolated platelets at very low concentrations (EC50 = 18 nM) via remodelling of the actin 
cytoskeleton, which is dependent on G12/13- mediated activation of the small GTP- binding 
protein, Rho and subsequently Rho kinase (Bauer et al., 1999; Retzer and Essler, 2000). LPA also 
stimulates the tyrosine kinase Src during shape change causing subsequent activation of the 
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tyrosine kinase Syk (Maschberger et al., 2000). Src and Syk, which are most likely Gi activated in 
platelets, can elicit an increased exposure of fibrinogen binding sites on the integrin αIIbβ3 which 
is a prerequisite for subsequent aggregation (Bauer et al., 2001). 
Higher concentrations of LPA were required to induce aggregation in isolated platelets (EC50 = 
10μM) (Benton et al., 1982) (Maschberger et al., 2000). Aggregation of washed platelets was 
considerably influenced by the concentration of albumin, and by fibrinogen (Benton et al., 1982). 
Benton et al showed that 1mg/ml bovine serum albumin (=15μM) was able to inhibit the platelet 
aggregation caused by 3μM of LPA. Due to albumin present in plasma much higher 
concentrations of LPA are needed to induce aggregation in platelet rich plasma (20-100μM) 
(Tokumura et al., 1987). Studies on the effects of a number of LPA analogues have shown a 
higher potency for highly unsaturated and long chain acyl – LPAs (such as C20:4) than for the 
LPA analogues with a shorter C18 fatty acyl group, such as an oleoyl group (18:1). Ether-linked-
LPAs had the strongest aggregating activity (Tokumura et al., 2002). 
When platelets are stimulated by thrombin they mostly produce acyl- LPA (18:2) and acyl- LPA 
(20:4) (Sano et al., 2002). Acyl- LPA (20:4) is a more potent platelet activator in inducing shape 
change than other acyl- LPA species (Rother et al., 2003; Tokumura et al., 2002). Compared to 
acyl-LPA (16:0) the (20:4) acyl- LPA- species was 6.5-fold more effective in inducing platelet 
shape change (Rother et al., 2003). However, alkyl- LPA (16:0) has been shown to have the 
greatest potency in inducing shape change, 18.5-fold more effective than acyl- LPA (16:0) 
(Rother et al., 2003).  
The study of Gueguen et al has determined varying extents of platelet aggregation for nine LPA 
analogues all showing cross-desensitization for the same LPA receptor (Gueguen et al., 1999).  
Also in the study of Guegen platelets have shown a decreased response to LPA in a medium 
containing 1.3 mM calcium, contrasting previous observations of Sugiura et al who showed the 
necessity of calcium for LPA-induced aggregation (Alberghina et al., ; Gueguen et al., 1999; 
Sugiura et al., 1994). Thus in our studies experiments acyl-LPA (16:0) and alkyl-LPA (16:0) will 
be analysed for inducing aggregation with regard to calcium dependency. 
2.3.6. LPA-receptors  
It is still unknown which LPA receptors mediate platelet activation and aggregation. LPA-
induced activation of platelets is possibly mediated by G- protein coupled LPA-receptors as they 
have been shown in a number of other cells. LPA activates possibly the three different types of 
G-protein coupled receptors, LPA1, LPA2, LPA3 receptors, formerly termed endothelial cell 
differentiation gene (Edg-2, -4, -7). All three LPA receptors have been found to be expressed in 
platelets as detected by RT- PCR (Motohashi et al., 2000). 
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However, by studying the effect of LPA-receptor activation with various subtype selective 
agonists and antagonists, LPA responses of platelets have shown to be inconsistent with the 
pharmacological properties of LPA1-3 of other cells (Hooks et al., 2001). 
The short chain phosphatidate, dioctanoyl glycerol pyrophosphate (DGPP 8:0), a selective 
antagonist of LPA1 and LPA3 with no effect on LPA2, antagonizes platelet activation (Fischer et 
al., 2001; Rother et al., 2003). DGPP 8:0 inhibited both acyl- LPA and alkyl-LPA responses 
(Rother et al., 2003), indicating LPA might therefore induce platelet activation through LPA1 and 
LPA3 receptors. In another study where platelets from some donors were non-responsive to the 
highly potent alkyl-LPA (16:0), the expression of LPA2 mRNA dominated over LPA3 and LPA1 
in those non-responders. This also suggests that LPA2 plays a less important role in LPA- induced 
platelet activation than LPA1 and LPA3 (Tokumura et al., 2002). This discrepancy could suggest 
that LPA responses in platelets are mediated by yet unidentified receptors or novel LPA receptors 
like LPA4 (Noguchi et al., 2003). 
Adding to the complexity is the discovery of the nuclear receptor PPARγ (peroxisome 
proliferator-activated receptor) as LPA-receptor (McIntyre et al., 2003). LPA-induced PPARγ 
activation was held responsible for LPA-induced formation of neointima in vivo in rat carotid 
arteries (Zhang et al., 2004).  
2.4. Platelet-monocyte interaction 
2.4.1. LPA-induced platelet-monocyte activation 
It is becoming increasingly apparent that circulating monocytes may represent a principle player 
in the inflammatory and coagulative pathways. Monocytes can adhere to and migrate through the 
dysfunctional endothelium into the intima and can thus mediate inflammatory responses in 
atherosclerotic lesions (Ross, 1999). 
High concentrations of LPA (0.1-0.3 mM) stimulate in human monocytes an increase in cytosolic 
Ca2+, chemotaxis, and their haptotactic migration. These actions are possibly related to the 
activation of LPA membrane receptors (Zhou et al., 1995). More recently LPA has been shown to 
induce a rise in intracellular Ca2+ in Mono Mac 6 cells at much lower concentrations (EC50 = 
52nM) (Fueller et al., 2003). These cells, a differentiated human monocytic cell line, expressed 
LPA1 and LPA2 receptors, similar as human blood monocytes and macrophages (Fueller et al., 
2003). Minimally oxidized LDL and serum also induced a rise in intracellular Ca2+ in Mono Mac 
cells and this action was mediated by the activation of LPA receptors (Fueller et al., 2003). 
However, another study showed that human blood monocytes express only LPA1, but not LPA2 
and LPA3 receptors (Lee et al., 2002a). Thus circulating or locally produced LPA might possibly 
stimulate macrophages and monocytes by LPA receptor activation.  
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2.4.2. Mechanisms of platelet-monocyte interaction 
Activated platelets may stimulate 1) inflammatory responses and 2) can have a procoagulant 
influence at the site of platelet activation. Upon activation, platelets can adhere to monocytes and 
thereby initiate monocyte activation (Larsen et al., 1989; Neumann et al., 1996; Ott et al., 1996; 
Rinder et al., 1991). It has first been demonstrated by Jungi et al that thrombin- stimulated 
platelets adhere to monocytes and neutrophils (Jungi et al., 1986). Monocytes have a competitive 
advantage over neutrophils when less potent agonists, like epinephrine and ADP, are used 
(Rinder et al., 1991). In this dissertation experiments on platelet-monocyte interaction in response 
to LPA were performed. 
The process of platelet-monocyte attachment is mediated by the platelet’s surface expression of 
P- selectin, an adhesion molecule contained in α-granules that appears on the membrane surface 
after degranulation. P- selectin is a member of a family of adhesive proteins including E- and L-
selectin that are known to regulate transient interactions between endothelial cells and leukocytes 
(Lasky, 1992). P-selectin interacts with its natural ligand, P-selectin glycoprotein ligand-1 
(PSGL-1), present on monocytes and neutrophils, providing an anchoring source for 
inflammatory cells on activated platelets (McEver and Cummings, 1997; Sako et al., 1993). Firm 
attachment is subsequently mediated by monocyte CD11/CD18- dependent platelet interactions 
(Cerletti et al., 1999). However, P- selectin may not be the only mode of attachment to 
leukocytes; additional molecules may be involved (Sarma et al., 2002). 
Activated monocytes may perpetuate inflammation by releasing metabolites of arachidonic acid, 
leukotrienes and interleukins (Feuerstein and Hallenbeck, 1987). Moreover, platelet-activated 
monocytes can initiate the extrinsic pathway of coagulation via surface expression of tissue 
factor, may influence rapid fibrin formation and facilitate adhesion to the endothelium via 
expression of the β2- integrin Mac-1(Altieri et al., 1988; Drake et al., 1989; Zillmann et al., 
2001). Experimental studies have demonstrated that platelet/leukocyte-interaction is involved in 
atherogenesis by neointima formation, luminal tissue factor expression and fibrin deposition 
(Kawasaki et al., 2001; Singh et al., 2001). 
The possible clinical relevance of platelet- monocyte interaction was shown by Furma et al. who 
demonstrated elevated levels of platelets attached to monocytes in patients with acute coronary 
artery disease (Furman et al., 2001). In patients with acute myocardial infarction the increase in 
platelet-monocyte aggregates, having a half life of about 30 minutes in vivo, did not correlate 
with the number of P-selectin-positive platelets which were previously believed to be the “gold 
standard” marker of platelet activation (Michelson et al., 1996; Michelson et al., 2001; Michelson 
and Furman, 1999). In fact Michelson et al has demonstrated that platelet-monocyte aggregates 
are a more sensitive marker than P-selectin of platelet activation in vivo. 
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3. Key Questions addressed 
 
The following thesis will present a functional study trying to disclose some of the mechanisms 
involved in LPA-induced platelet activation, in particular aggregation and platelet-monocyte 
interaction. 
 
It is known that LPA can cause platelet shape change and platelet aggregation. However, a 
systematic study concerning the mechanism of LPA- induced aggregation in washed platelet 
suspensions and platelet rich plasma is missing; and it is unknown whether LPA induces platelet 
aggregation in whole blood. 
 
The following issues will be addressed: 
• Determining the potency of LPA as a platelet agonist in washed platelets, platelet-rich 
plasma and blood 
• Establishing a possible donor- dependent LPA-induced platelet response 
• Discovering which mediators are involved in LPA-induced platelet aggregation 
• Discerning inhibitors of LPA-induced platelet activation 
• Finding out whether LPA can induce platelet adhesion to monocytes and by which 
mechanism the adhesion could be mediated 
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4. Materials and methods 
4.1. Materials 
Adenosine-3´, 5´Diphosphate, Sodium Salt Sigma 
Adenosine-5´-Diphosphate (ADP), Disodium Salt Sigma 
Albumin, bovine; Fraktion V;  
Prod.-Nr. A2153 
Sigma 
Albumin, bovine; essentially fatty acid free; 
Prod. -No. A7511 
Sigma 
Apyrase;  Prod.-No. A6535 Sigma 
ARC-69931 MX; 
Code- No. 1-407-526, Batch-No. 4256J 
Astra Zeneca 
Calciumchloride (CaCl2 × 2 H20) Merck 
CAMP Correlate-EIA Kit; Prod.-No.  90066 Biotrend 
CD 14- PE; clone: MφP9, Prod.-No. 347497 BD, Biosciences 
CD 41a- FITC; clone: HIP8 anti GPIIb;  Prod. No. 555466 BD, Biosciences 
Creatine phosphate / Creatine phosphate kinase Sigma 
Collagen (Kollagenreagens ”Horm“) and SKF Horm® Buffer Nycomed Pharma Gmbh 
Diacylglycerolpyrophosphate Avanti Polar Lipids 
Dimethylsulfoxide (DMSO) Sigma 
Ethane- N,N,N’,N’ Tetra- Acetic- Acid (BAPTA-AM); Prod.–
No. A1076 
Sigma 
Ethanol, absolute Merck 
Ethylendiaminetetraacetate (EDTA); disodiumsalt, dihy- 
Drate 
Sigma 
Ethyleneglykol—bis(β-Aminoethylether)-N,N,N´,N´-Tetra- 
 Acetate (EGTA) 
Sigma 
Fluorescein Isothiocyanate (FITC)- conjugated mouse IgG1, κ 
monoclonal Immunoglobulin Isotype Standard, clone: MOPC- 
31C, Prod.-No.550616 
BD, Biosciences 
Formaldehyde-Solution at least 37% Sigma 
Gelsolin, from bovine plasma; Prod.-No. G8032 Sigma 
Gelsolin, from human plasma; Prod.-No. G1583 Sigma 
D(+)-Glucose-Monohydrate Merck 
Hepes, N-[2-Hydroxyethyl]piperazine-N´-[2-ethane- sulfonic-
acid 
Sigma 
Iloprost ; Prod. No. SH-L-401A Schering 
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Potassiumdihydrogenphosphate (KH2PO4) Merck 
Potassiumchloride (KCl) Merck 
Prostaglandin E1, Prod. No. P5515 Sigma 
Oleoyl-L-α-Lysophosphatidic Acid (C18:1, [cis]-9), Sodium 
Salt 
Sigma 
1-Palmitoyl-sn-glycero-3-phosphate (P-LPA; 1-acyl-LPA 
16:0) 
Alexis Corp. (San Diego, CA, 
USA).   
Platelet activating factor 
(β-Acetyl-γ-O-Hexadecyl-L-α-Phosphatidylcholin) 
Sigma 
P-Selectin- Antibody, CD62p-FITC, subclass IgG1 Prod.- No. 
MCA796F 
Serotec 
P-Selectin Monoclonal Blocking Antibody, Clone G-1, 
subclass IgG1 Prod.-No. BMS 126 
Bendermedsystems 
PGE1 [11α, 13E, 15S]-11,15- Dihydroxy-9-oxoprost-13-enoic 
acid; Prod.-No. P5515 
Sigma 
Red Blood Cell Lysing solution, Erythrolysis Serotec Ltd 
Refludan 
Pharmion Ltd. c/o 
LOGOSYS Logistic GmbH 
RGDS (Arg-Gly-Asp-Ser) Sigma 
SKF-96365, Hydrochlorid (1-[β-[3-(4-Methoxyphe- 
 nyl)propoxy]-4-methoxyphenylethyl]-1H-imidazol) 
Calbiochem 
Tissue Factor- Antibody, TF-FITC, clone I, subclass IgG1 , 
Prod.- Number: 9010-5079 
Biotrend 
Thrombin Receptor Activator Protein (TRAP), Prod. No S-
7152 
Sigma 
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4.2. Buffers 
Acid- Citrate- Dextrose 85 mM  
111 mM 
65 mM 
Trisodium Citrate 
Glucose 
Citric Acid 
BSA- Buffer: 150 mM 
10 mM 
0,25 mM 
NaCl 
Hepes 
Bovine Serumalbumine 
Fixing Solution (pH 7.4) 150mM 
4.6 mM 
4.5 mM 
1.6 mM 
0.16% w/v 
NaCl 
Na2EDTA 
Na2HPO2 
KH2PO4 
Formaldehyde 
 
Buffer B (pH 6.2) : 20 mM 
138 mM 
2.9 mM 
1 mM 
0.36 mM 
Hepes 
NaCl 
KCl 
MgCl2 
NaH2PO4
 
Buffer C (pH 7.2): See Buffer B 
 
Solution I 16.0g 
0.4g 
2.0g 
0.116g 
NaCl 
KCl 
NaHCO3 
NaHPO4. H2O 
4.3. Methods 
4.3.1. Preparation of LPA 
Both phospholipids palmitoyl-LPA and oleoyl-LPA were dissolved in 80% ethanol/ 20% H2O 
solution to create a 1mM stock solution stored at -20°C.  The ethanol containing LPA solution 
was used up to a final concentration of 3μM.  Any concentration higher than 3μM of LPA was 
taken from BSA buffered solution LPA stock (see section above for BSA).  BSA buffered LPA 
stock was obtained by vaporizing a certain volume of LPA dissolved in ethanol using Nitrogen 
gas.  The LPA sediment was dissolved in an equal volume of BSA buffer to create a 1mM LPA 
solution. 
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4.3.2. Preparation and Incubation of other agonists and antagonists 
All but the following agonists and antagonists were dissolved in 0.9% NaCl. 
Collagen was dissolved in SKF Horm® Buffer at a concentration of 100μg/ml. 
For experiments in whole blood, aspirin was dissolved at pH 7 (maximum solubility of 3.3g/l) in 
0.9% NaCl and drawn together with the anticoagulant into a separate syringe to be mixed with 
whole blood to obtain a 1mM final concentration. 
In experiments with washed platelets and PRP asprin was dissolved in absolute ethanol. 
BAPTA- AM was dissolved in DMSO to create a 20mM stock.  
The following platelet inhibiting antagonists were used: apyrase (10 U/ml), P2Y1 receptor 
antagonists MRS2179 (100 µM) and A3P5P (200 µM), P2Y12 receptor antagonist ARC69931 (1 
µM), P- selectin antibody,  Ca2+ binding molecule EGTA (1mM) and BAPTA-AM (10- 200 μM) 
and SKF 96365 (100μM), fibrinogen binding molecule RGDS (5 mM). All the ADP inhibitors 
were added 30 sec prior to adding the agonist. When working with a P- selectin antibody, the 
antibody was also added 30 sec prior to the agonist. The Ca2+ binding molecule, EGTA (1 mM), 
was added 10 sec before agonist addition. BAPTA-AM and SKF 96365 were pre-incuabted at 37 
°C for 30 minutes and 10 minutes, respectively 
In platelet- rich-plasma experiments and washed platelets aspirin was preincuabted at 37 °C for 
10 min. In experiments with whole blood aspirin was directly dissolved in the anticoagulant when 
drawing blood. Therefore, incubation time in whole blood depended on the experiment, but was 
at least 20 minutes. 
4.3.3. Blood Preparation 
Blood from healthy volunteers not taking any medication was drawn by cubital venipuncture into 
propylene syringes containing either tri-sodium-citrate dihydrate (3.8% w/v) 1:10 or recombinant 
hirudin (Refludan®; 13µg/ml; 200U/ml). A winged infusion set (0.8 X 20 X 300 mm) was used 
and blood was immediately transferred into polystyrene tubes and kept at 20°C during platelet 
isolation. Experiments were completed within 2 hours after drawing blood. 
4.3.4. Preparation of Platelet-Rich-Plasma (PRP) 
For PRP whole blood was centrifuged at 180g for 20 min until platelet rich plasma (PRP) had 
separated from erythrocytes and leukocytes. The supernatant of PRP was transferred carefully 
without disturbing the buffy coat and red blood cell layer into a capped polystyrene tube and kept 
at room temperature. The remainining PRP was centrifuged at 1500g for 10 min to produce 
platelet poor plasma in order to gage the aggregometer to 100% light transmittance. 
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4.3.5. Preparation of washed platelets 
 
Fig 4.1 
Summary of different platelet preparations 
ApyA or A alone stands for apyrase in a final concentration 0.3 U/ml. Buffer C stands for CP/CPK containing buffer.  
ACD stands for Acid-citrate- dextrose and functions similar to EGTA as a Ca2+ chelator.  
4.3.5.1. Method 1 
Whole blood anticoagulated with either tri-sodium-citrate dihydrate (3.8% w/v) 1:10 or 
recombinant hirudin (Refludan®; 13µg/ml; 200U/ml) was centrifuged at 180g for 20 min. The 
top layer of PRP was carefully separated with a large pipette into a separate 50 ml capped 
polystyrene tube. Then the COX-1 inhibitor, aspirin 1 mM, and ADP scavenger enzyme, apyrase 
0.3 U/ml final concentration (f.c.) was added to PRP and incubated at 37°C for 15 minutes. 
Subsequently citric acid 9mM and EDTA 5mM (f.c.) were added in order to bind excess Ca2+ 
preventing the formation of ionized Ca2+ needed for clotting.   
Following centrifugation at 800g for 20 min the supernatant was discarded and the platelet pellet 
resuspended in buffer B stored at 37 °C prior to suspension. The volume of buffer B was 
determined by 15% the original blood volume.  0.3 U/ml apyrase (f.c.) was dissolved in buffer B 
before resuspending the pellet.  A final centrifugation at 800g for 20 min was needed to 
resuspend the platelets in buffer A also stored at 37°C. 0.3 U/ml Apyrase and 5 mM glucose were 
added to buffer B prior to suspension. The volume of buffer C was calculated to obtain a final 
platelet count of 400 000/μl.  
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4.3.5.2. Method 2 
In addition, a modified version of platelet preparation of method 1 was implemented. The 
modified version followed the above platelet preparation closely up to the point of incubation of 
PRP. In addition to aspirin and apyrase PRP was incubated with PGE1 (2μM) in order raise 
cAMP levels via inhibition of Gi.  In any of the subsequent steps apyrase was replaced by 
Creatinphosphate (CP 1mM)/ Creatinphosphate Kinase (CPK 10U/ml), catalyzing the following 
reaction: Creatinphosphate + ADP ←→ Glucose-6-phosphate + ATP. 
The platelet pellet was subsequently resuspended in buffer C, which equals buffer B excepts with 
a higher pH.  
4.3.5.3. Method 3 
In this method PRP was acidified to a pH of 6.4 with acid-citrate-dextrose and centrifuged at 
800g for 20 min. The platelet pellet was resuspended in buffer C. 
4.3.5.4. Method 4 
Preparation of washed platelets for measuring aggregation and serotonin secretion. Platelets were 
prepared as described by Gachet et al (Cazenave JP, 1993). Blood was collected into a 50ml 
propylene syringe containing 1 volume of anticoagulant ACD (see buffers) for 6 volumes of 
blood (final pH 6.5 and citrate concentration 22 mM). Blood is centrifuged for 15 minutes at 
1000 rpm (175 x g) to obtain PRP. After removing this portion and incubating for 15-30 minutes 
at 37°C, PRP is centrifuged at 3000 rpm (1570 x g) for a period of time depending on the plasma 
volume: 
Plasma volume (ml)   15 20 25 30 35 40 
Centrifugation time (min)  10 12 13 14 15 16 
The supernatant, platelet-poor-plasma, is carefully and completely removed to avoid the 
generation of thrombin during subsequent washing steps. Platelets are then resuspended in the 
first wash solution, prewarmed to 37°C, with the addition of 1 μl/ml prostacyclin, PGI2 1 mM. A 
wash volume of 10 ml is normally required for the platelet pellet derived from 50-100 ml of 
blood. The platelet suspension is transferred to a closed test tube and incubated at 37°C for 10 
minutes. Then 1 μl/ml of PGI2 is added followed by centrifugation for 8 minutes at 2600 rpm. 
The platelet pellet is then resuspended in the final suspension medium (20 ml), Tyrode buffer 
containing 2 mM CaCl2, and 0.35 % fatty acid free human albumin at a density of 3x105 
platelets/µl. 0.02 U/ml of the ADP scavenger apyrase were added.  Platelets were kept at 37°C 
throughout all experiments. 
When required, cytoplasmatic labeling of platelets may be performed by incubation in the first 
wash slolution with [3H]serotonin (0.2 μCi/ml) according to (Gachet et al., 1995; Ohlmann et al., 
2000). 
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4.3.6. Measuring shape change and aggregation in washed platelets and 
platelet- rich- plasma (PRP) 
All of the experiments measuring shape change and aggregation in washed platelets and PRP 
were performed in a LABOR® aggregometer (Fa. Fresenius, Bad Homburg, Germany) at 37°C 
under stirring (1000 rpm) by the turbidimetric method of Born. 400μl aliquots of PRP or platelet 
suspension were placed into transluscent plastic cuvettes containing magnetic stirring-bars and 
incubated for 1 min before being placed on the magnetic stirrer base of the aggregometer.  After 
30 to 90 seconds of stirring the different agonists were added directly to the samples of platelet 
suspension and platelet shape change or aggregation were recorded in % decrease or increase in 
light transmission with a fine-needle writer.  
Light transmission of unstimulated PRP represents 0 % aggregation the light transmission of PPP 
100 % aggregation. Platelet shape change was recorded as a reduction in light transmission 
caused by negative deflection of light. 
4.3.7. Aggregation in blood 
Whole blood platelet aggregation was measured using the single-platelet counting technique 
described by Heptinstall et al with the following modifications(Fox SC, 1982). Aliquots (400µl) 
of anticoagulated blood samples were placed into aggregometer cuvettes and incubated 2 min at 
37 ° C. The samples were stirred in the LABOR® aggregometer (section 4.2.6) at 300 rpm for 30 
sec. The inhibitor/antagonist was added and incubated for 30 sec before adding LPA (1µM- 
20µM, from a 1 mM stock solution dissolved in albumin buffer (section 4.1.2). Other antagonists 
except aspirin were added in the same manner than for PRP experiments. 
Aliquots (15µl) were removed at time 0 for baseline count and at set time intervalls therafter. The 
15μl were placed in 30µl of fixing solution.  After dilution to 1 ml  the  samples were centrifuged 
at a speed set by the Sysmex® Platelet Centrifuge PC-800 (Toa Medical Electronics, Japan) and 
counted using a platelet counter (Sysmex® Platelet Counter PL-100, Toa Medical Electronics, 
Japan). The percentage aggregation calculated as percentage loss of single platelets compared to 
baseline count. All platelet counts were done in duplicates.   
The samples were removed at predetermined time intervals in order to obtain a time dependent 
course of aggregation. The samples needed to remain at least 30 min in fixing solution before 
platelet count was performed. 
4.3.8. Measuring cAMP levels in platelets 
In washed platelets according to method 1 cAMP levels were determined with an enzyme- 
immuno- assay (EIA) Kit (Assay Designs, Inc). 
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The platelet suspension, adjusted to 1 million cells/μl, was incubated with the stable prostacyclin 
analog, Iloprost (50 nM), for 5 minutes 37 °C in order to raise cAMP levels. Platelets were then 
stirred at 1000 rpm for 30 seconds until the platelet stimulant, LPA (0.1 – 40 μM), ADP (5 and 
50 μM) or epinephrine (10 μM) was added. After 2 minutes of stirring the platelets were lysed in 
a 0.1M HCl (f.c.) solution. All samples were measured in duplicates.  After 5 minutes all platelets 
had been been subject to lysis and the samples were centrifuged at 1000g for 5 minutes. The 
supernatant was placed into a 64-well microplate pre-coated with an antibody.  
The principle of measuring cAMP can be seen in the figure below. cAMP in the supernatant from 
lysed platelets competes with cAMP conjugated to alkaline phosphatase. Alkaline phosphatase 
has the ability of splitting paranitrophenylphosphate producing a yellow color of the end product. 
The bound yellow color is inversely proportional to the concentration of cAMP.  
The measured optical density is used to calculate the concentration of cAMP in  
pmol/ 106 platelets. 
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Fig 4.2 
Principle of  the enzyme immono assay (EIA) when measuring camp 
cAMP in the supernatant from lysed platelets competes with cAMP conjugated to alkaline phosphatase. Alkaline 
phosphatase splits paranitrophenylphosphate producing a yellow color. The bound yellow color is inversely 
proportional to the concentration of cAMP. 
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4.3.9. Quantifying platelet aggregates and platelet-monocyte- aggregates 
(PMA) and P-selectin expression 
4.3.9.1. Preparation of whole blood samples and measuring aggregation FACS analysis 
400μl aliquots of hirudinized blood as described for blood. The stirrer was set to a speed of 1000 
rpm and timed to 5 min. The agonist was added prior to stirring and the reaction stopped after 5 
minutes by placing 100μl of blood sample in red blood cell (RBC) lysing solution. Centrifuging 
the lysed samples at 3000 rpm for 5 minutes allowed the removal of RBC debris. Washing the 
pellet with 1ml PBS, centrifuging at 3000rpm for 5 minutes, removed most of the lysing solution. 
This step was followed by incubation with antibodies. CD 14-PE binds to a monocyte specific 
glycoprotein marking all the monoctes. As a second antibody monoclonal CD 41a- FITC binding 
to GPIIb part of the fibrinogen receptor on platelets was used to stain platelets. The unspecific 
binding was determined with a FITC-conjugated IgG1 isotype control antibody. All samples were 
incubated for 15 min at room temperature in the dark followed by resuspension in 600μl PBS. . 
4.3.9.2. Measuring P-selectin expression in platelets isolated by method 4 
For P-selectin expression, platelets (1.5 x 108) were incubated for 15 min with 0.5 mg anti-CD62-
PE antibody, and 0.5 ml Tyrode’s buffer containing 2 mM CaCl2 and 0.35 % fatty acid free 
albumin was added. Mean fluorescence intensity was measured by FACS after collecting 10000 
platelet events. The mean fluorescence intensity of isotype-matched IgG1-PE was substracted 
4.3.9.3. Principle of FACS analysis 
The principle of Flow Cytometry is analyzing the light signals generated by particles as they flow 
through a liquid stream past a light beam. An argon laser beam emitting light at 488 nm 
constitutes the light source. The argon laser is focused to an elipse of 20μm by 60μm in size. The 
smaller height of 20 μm avoids the simultaneous analysis of two cells being in the beam at the 
same time. Two cells closer than 20μm together would be counted as one event, thus there is an 
ideal cell density of under 1 million cells/μm.  
While cells are in the laser beam illumination signals and fluorochrome signals are collected 
simultaneously. The illumination signals are collected by the first lens positioned in the forward 
direction of the laser beam and the second lens positioned at a right angle to the laser beam. The 
light collected head on is not the laser light directly, but it is light that has been slightly refracted 
by the cell and strikes the forward positioned lens indicating the size of the cell. The laser light 
striking the forward positioned lens directly is being blocked by a centrally located obscuration 
bar. Light hitting the forward scatter lens is focused onto a photodiode where it is converted to an 
electrical current. In a similar manner the sideward positioned lens collects light that has been 
scattered to wide angles from the original direction of the beam. Irregularities in the cell cause 
this wide angle scatter indicating the granularity of the cell. 
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The type of cell was identified using fluorescently tagged antibodies, CD 41a and CD14,  
targeting surface molecules specific for platelets and monocytes. The fluorochromes conjugated 
onto the antibodies are transferred to a higher energy state and emit their defined fluorescent 
signals when exciting by the laser beam.  
These signals are collected by the same right-angle lens that collects side scatter light. The light is 
subsequently partitioned according to its color, in this case, FITC - green and PE - red. 
Afterwards these light signals are converted into a data file via electrical current produced with 
the help of Photodiode detectors and Photomultipliers. The conversion from electrical current to 
the computer was done on a Mac Intosh Computer using Cellquest as a software program. 
4.3.9.4. Statistical analysis 
Statistical Analysis was completed with Excel 2000 (Microsoft). The results represent statistical 
mean and mean standard of deviation from which significance was calculated via student’s t-test 
for paired values.  P<0.05 was considered to be significant. 
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5. Results 
5.1. Response of washed platelets to LPA: Comparison of different 
platelet isolation procedures 
The purpose of testing washed platelets, separated from their physiological medium, was to 
demonstrate the direct effect of LPA on platelets excluding any cofactors from plasma or other 
cells. Moreover, washed platelets allowed us to define other plasma factors interfering with the 
action of LPA on platelets. 
Since there are different biochemical structures of LPA, varying in biological activity, the term 
LPA refers to 1- acyl LPA (16:0) throughout the text unless mentioned otherwise.  
5.1.1. LPA only induced shape change of platelets isolated according to 
method 1 and method 2 
LPA induced the initial platelet activation, shape change, in washed platelets prepared by method 
1 and method 2. Platelets, however, did not aggregate in response to low (5μM) or high (120 μM) 
LPA concentrations. The LPA concentrations tested ranged from 5μM to 120μM. Even the 
addition of fibrinogen (0.1-1 mg/ml), plasma (2-20 %), Ca2+ (1mM), alone and in combination of 
both or all three, did not show aggregation, only shape change as the sign for initial platelet 
activation (Fig5.1). 
  method 1     method 2 
  80 μM LPA + 10% PPP   80 μM LPA + 10% PPP 
 
 
 
 
 
 
Fig 5.1 
LPA induced shape change in platelets washed by method 1 and 2 
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Platelets isolated by method 1 and method 2 were either incubated for 2 minutes at 37°C and stirred for 1 minute at 
1000 rpm at 37°C before 80 μM of LPA + 10 % PPP was added. LPA induced shape change but no aggregation in 
these platelets. Tracings recorded by aggregometry represent experiments of washed platelets from different donors 
(n=20). 
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In order to explore whether LPA might amplify the aggregation response induced by ADP (5 
μM), ADP was added together with LPA in the presence of 5 % platelet poor plasma (PPP). As a 
result the ADP-induced aggregation was amplified (Fig 5.2). ADP in the absence of PPP did not 
induce platelet aggregation (data not shown).  
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Fig 5.2 
ADP induced aggregation in platelets isolated by method 1 is amplified by LPA 
Washed platelets (method 1) were incubated for 2 minutes and stirred for 1 minute at 1000 rpm at 37°C in the 
presence of platelet poor plasma (PPP; 5%). ADP (5μM) was added alone or together with LPA (80 μM), 
simultaneously. Aggregation tracings are representative of 6 experiments. 
5.1.2. LPA induced aggregation of platelets isolated according to method 3 and 
method 4 
Platelets prepared according to method 3 showed irreversible platelet aggregation, which was 
observed after low concentrations of LPA (1μM) (Fig 5.3). 
However, when looking at these aggregation tracings closely, no rapid oscillations at baseline 
were apparent and no shape change in response to LPA was observed. In addition the aggregation 
response to LPA declined 60 minutes after venipuncture and disappeared in most of the 
experiments with increasing time. 
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  1 μM LPA     1 μM LPA 
  after 30 minutes    after 60 minutes 
Fig 5.3 
LPA induced aggregation in platelets isolated by method 3 
Platelets were stirred at 1000 rpm for 1 minute at 37°C before the addition of LPA (1 μM). No plasma was added. 
Platelet aggregation was recorded by aggregometry within 30-60 minutes after venipuncture. Tracings are 
representative of 40 experiments. 
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Fig 5.4 
LPA induced shape change followed by aggregation in platelets isolated by method 4 
Washed platelets (suspended in Tyrode with fatty acid free albumin 0.35% (w/v) 3x108 platelets /ml) were stirred at 
1000 rpm in the presence of fibrinogen and buffer at 37°C before 1-100μM LPA were added. Secretion of tritiated 
serotonin is indicated in brackets. 
Platelets prepared according to method 4 showed shape change followed by aggregation in 
response to LPA. The platelet response did not diminish when the platelet suspension was kept at 
37°C for a time period of 3 hours. In contrast to the platelet isolation procedure with method 3, 
platelets were washed in the presence of prostacyclin, heparin and resuspended in buffer 
containing apyrase to avoid platelet pre-activation and desensitization of the ADP receptor P2Y1 
(Baurand et al., 2000; Cazenave et al.). 
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Using this platelet preparation, a concentration of 1μM LPA induced shape change. 3μM LPA 
induced shape change and reversible aggregation. Higher concentrations (10, 30, 100μM) of LPA 
elicited maximal irreversible aggregation. Serotonin secretion increased proportional to the LPA 
concentration added (Fig 5.4). 
Figure 5 shows the dose-response curve of aggregation induced by LPA in platelets prepared by 
method 4. Aggregation starts with only 3μM LPA and maximal aggregation is reached with 
30μM (Fig 5.5).  
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Fig 5.5 
Dose –response of 1-acyl-LPA (16:0) induced aggregation in platelets isolated by Method 4 
Washed platelets (suspended in Tyrode with fatty acid free albumin 0.35% (w/v) 3x108 platelets /ml) were stirred at 
1000 rpm in the presence of fibrinogen and buffer at 37°C before 1-100 μM LPA were added (mean ± SD, n=3).  
5.2. LPA-induced shape change in washed platelets, PRP, and whole 
blood 
5.2.1. Shape change induced by LPA in washed platelets and in the presence of 
albumin or plasma 
It was previously observed that a 500-fold lower concentration of LPA was needed to induce 
platelet shape change in washed platelets isolated by method 1 (EC50 of 11nM) than in PRP (EC50 
of 4μM) (Rother et al., 2003). Thus, we suspected inhibiting factors present in PRP to be 
responsible for this difference in activation. In searching for these factors we thought of two 
possible substances known to interact with LPA: albumin and gelsolin (Goetzl et al., 2000; 
Thumser et al., 1994); see section 1.3.4). 
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Here we compared shape change in washed platelets adding LPA (50 nM), together with albumin 
(1-65μM) or platelet poor plasma (PPP 1-10%). Shape change was measured under stirring 
conditions in an aggregometer. PPP was used for comparative analysis to determine whether 
albumin was the only inhibiting factor of plasma. The plasma volume added was calculated to 
contain the same amount of albumin as human fatty acid- free albumin that was added separately. 
The amount of albumin in PPP was calculated based on the average amount of albumin contained 
in plasma (45g/l; 0.66mM). 
The results show that the LPA- induced shape change was inhibited by increasing concentrations 
of PPP or albumin. However, PPP inhibited the LPA-induced shape change to a greater degree 
than albumin alone. 60μM of albumin were required, when added alone (IC50 13 μM), whereas 
45μM albumin in plasma were required to inhibit shape change completely (IC50 5 μM) (Fig 5.6).  
Therefore, albumin seems to be an important, but not the only factor present in plasma inhibiting 
the LPA-induced platelet shape change. 
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Fig 5.6 
Dose- response curves comparing the inhibiting effect of albumin and albumin contained in plasma on LPA- induced 
platelet shape change in washed platelets 
Washed platelets isolated according to method 1 were stirred for 1 minute at 1000 rpm at 37 °C before simultaneous 
addition of albumin + 50nM LPA or PPP (platelet poor plasma) + 50nM LPA (mean ± SD, n=22).  The amount of 
albumin in plasma was calculated assuming the average plasma albumin concentration of 45g/l or 0.66mM. 
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5.2.2. Shape change induced by LPA in washed platelets in the presence of 
gelsolin 
Since albumin does not seem to be the only factor responsible for the inhibition of shape change 
seen by plasma, we tried to find other plasma contents contributing to the effect. Gelsolin has 
been shown to strongly interact with LPA and has also been found in plasma (Goetzl et al., 
2000); (see section 1.3.4).  
Based on a previous study plasma gelsolin added in low concentrations, < 10% plasma level (<  
0.12 μM), is expected to enhance LPA activity and added in high concentrations, > 20% of the 
plasma level > 0.59 μM), is expected to suppress LPA activity (Goetzl et al., 2000). When adding 
these concentrations prior to and simultaneously with LPA to washed platelets (method 1), 
neither concentration showed any effect on LPA- induced shape change.  
Another study showed evidence that intracellular gelsolin activity is Ca2+ dependent. This raised 
the possibility that gelsolin may be capable of binding LPA and delivering it to its cellular 
receptors only in the presence of extracellular Ca2+. Thus we carried out experiments in the 
presence of Ca2+, to exclude a failure in gelsolin activity due to lack of Ca2+. However, platelet 
shape change remained unchanged in response to 50nM LPA+ Ca2+ (1 mM). Even very high 
concentrations of gelsolin up to 1μM did not affect shape change (Fig 5.7). These results indicate 
that plasma gelsolin had no effect on the interaction of LPA with platelets. 
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 Gelsolin (1 μM) +    H2O (11 μl) + 
 LPA (50 nM)      LPA (50 nM)  
      
Fig 5.7 
Shape change induced by LPA in washed platelets remains uninfluenced in the presence of gelsolin  
Washed platelets prepared by method 1 were incubated for 2 minutes and stirred for 1 minute at 1000 rpm at 37°C in 
the presence of gelsolin (1μM) before 50nM LPA was added. Shape change tracings measured by aggregometry 
representative of 6 experiments. 
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5.2.3. Shape change induced by LPA of washed platelets, PRP and blood is 
mediated by Rho-kinase activation – but independent of ADP receptors P2Y1 
and P2Y12  
Many platelet stimuli induce shape change independent of additional platelet activators such as 
ADP and thromboxane A2. To explore whether LPA- induced shape change is independent of 
released ADP, the ADP receptor antagonists MRS2179 (a P2Y1 receptor inhibitor) and ARC 
69931MX (P2Y12 receptor inhibitor) were used. They showed no inhibitory effect on platelet 
shape change in washed platelets and PRP (results not shown). 
Shape change induced by LPA showed a similar dose response curve, whether this response was 
induced in PRP or in blood (Fig 5.8a). This indicates the independence from red blood cells and 
suggesting the independence from ADP. Indeed, the P2Y1 receptor antagonist, MRS2179, and the 
P2Y12 receptor antagonist, AR-C69931MX or the combination of both antagonists did not inhibit 
LPA-induced shape change in whole blood (Fig 5.8b). The control experiments show that – as 
expected- MRS2179 but not AR-C69931MX blocked the ADP-induced shape change in PRP and 
whole blood (Fig 5.8b). Together these results indicate that LPA induces shape change 
independent of synergistic interaction with ADP.  
LPA-induced shape change of washed platelets is mediated by Rho-kinase activation (Retzer and 
Essler, 2000). Consistent with this result it was observed, that LPA-induced platelet shape change 
in blood could be inhibited by the Rho-kinase inhibitor Y27632. 
Also pre-treatment of platelets with aspirin had no effect on LPA-induced shape change, neither 
in washed platelets, PRP (results not shown), nor in blood (Fig 5.8b). Therefore LPA-induced 
shape change seems to be independent of thromboxane.  
In contrast to the donor-dependent variation of LPA-induced aggregation (see section 5.3.1), 
LPA-induced shape change of PRP and blood was observed in all blood donors tested.  
5.2.4. Comparison of 1-acyl-LPA (16:0) and 1-alkyl-LPA (16:0)- induced shape 
change in PRP and in whole blood  
It has been shown recently that 80% acyl-LPA and 20% alkyl-LPA is present in atherosclerotic 
plaques (Rother et al., 2003).  We determined the potency of the two different LPA species, 1-
alkyl-LPA (16:0) and 1-acyl-LPA in inducing shape change and aggregation. The results 
identified 1-alkyl-LPA (16:0) to be almost 20- fold more potent than 1-acyl-LPA in inducing 
shape change of PRP (Fig 5.8a). 1-Alkyl-LPA (16:0) was also more potent than 1-acyl-LPA 
(16:0) in inducing shape change of washed platelets and in whole blood (data not shown and 
section 5.3.3).  
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Fig 5.8 
LPA induces platelet shape change directly in blood and in PRP. 1-alkyl-LPA is a more potent activator than 1-acyl-
LPA in blood and in PRP. 
a) Dose-response curves comparing the effect of 1-alkyl-LPA (16:0) and 1-acyl-LPA (16:0) in inducing shape 
change of PRP. Shape change in ACD-PRP was measured by aggregometry (left y-axis). Shape change induced by 
1-acyl-LPA (16:0) in blood was measured by flow cytometry (right y-axis). Values are mean ± SD of 4-6 
experiments. P< 0.01 for the shape change induced by all concentrations of LPA. b) Citrated blood was pre-
incubated for 30 minutes with Rho kinase inhibitor Y27632 (20μM) or for 30 seconds with the P2Y12 receptor 
antagonist AR-C69931 (1μM), P2Y1 receptor antagonist MRS2179 (100μM), before addition of buffer (control), 
20μM 1- acyl LPA (16:0), or 5 μM ADP for 5 minutes. Shape change was measured by flow cytometry. Values are 
mean ± SD of 4 to 5 experiments. * P < 0.01 as compared to buffer plus stimulus. 
5.3. LPA -induced aggregation in PRP and whole blood 
5.3.1. LPA induced platelet aggregation and ATP secretion in PRP: donor 
dependent variations 
It was observed that the LPA concentrations needed to induce aggregation in PRP varied from 
donor to donor.  Concentrations of 10 μM LPA were sufficient to induce aggregation in some 
donors but concentrations of 80 μM LPA were necessary to induce aggregation in others. The 
same donor platelets consistently showed the same strong or weak aggregation response to LPA. 
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Platelet concentrations were not adjusted. However individual platelet count differences did not 
correlate with sensitivity to LPA (data not shown).  
Three distinct groups of LPA-induced aggregation response could be distinguished (Fig 5.9). 
Representative aggregation tracings above each dose response curve show a reversible 
aggregation in group 1 and 2 and an irreversible aggregation in group 3. The irreversible 
aggregation is known to be associated with granule release and subsequent amplification of 
aggregation. 
In order to find out whether reversible aggregation correlates with granule release, we measured 
LPA- induced aggregation and simultaneous secretion of ATP. As shown in Fig 5.10, LPA 
induced reversible aggregation, which was paralleled by rapid ATP secretion.  
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Fig 5.9 
Above: Representative tracings from LPA-induced aggregation in PRP from different blood donors 
PRP was stirred for 1 minute at 1000 rpm at 37°C before 80 μM LPA was added. Aggregation was recorded by 
aggregometry. 
Below: Dose response curves of LPA-induced aggregation of PRP from different blood donors 
LPA- induced maximal aggregation was recorded by aggregometry as % of maximum aggregation induced by 5μM 
ADP (100%). Each line represents the aggregation of a different donor (A-L). 
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Fig 5.10 
Representative LPA-induced aggregation tracings and secretion of ATP in PRP.  Effect of ADP receptor-antagonists 
PRP was stirred for 1 minute at 1000 rpm at 37°C before LPA (80μM) was added. The P2Y1 and P2Y12 ADP-
receptor antagonists, A3P5P (200μM) and AR-C69931MX (1μM) (ARC) were added 15 seconds prior to LPA 
addition. Aggregation (% light transmission) and simultaneous ATP secretion were recorded in a Lumi-
aggregometer. 
 
5.3.2. Low concentrations of LPA induced aggregation in whole blood 
When stirring whole blood at different speed (1000 rpm, 500 rpm, and 300 rpm) for 1 minute we 
observed different spontaneous aggregation responses, varying from 46± 6%, 29± 3%, to 17± 5 
% (mean ± SD, n=3), respectively, after 1 minute of stirring (Fig 5.11). Therefore, we minimized 
spontaneous aggregation due to stirring by choosing the lowest stirring speed (300rpm) in all 
experiments in whole blood. 
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Fig 5.11 
Time course of spontaneous aggregation at different stirring speed (1000 rpm, 500 rpm, and 300 rpm)  
Whole blood anticoagulated with hirudin was stirred in the presence of buffer at different speeds. Platelet 
aggregation was measured at 30, 60, 90, and 150 seconds of stirring. Percent aggregation is defined by the loss of 
single platelets (0 single platelets =100% aggregation).  Values are mean ± SD, n=3.  
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Fig 5.12 
Time course of aggregation induced by different concentrations of 1-acyl-LPA (16:0) in LPA-sensitive donors 
Whole blood anticoagulated with hirudin was stirred for 1 minute at 300 rpm at 37°C before different LPA 
concentrations were added.  Values are mean ± SD, n=7. 
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Aggregation in whole blood could be induced by LPA concentrations about ten times lower (EC50 
range 2-5 µM LPA) than in PRP (EC50 range, 40-65 µM LPA). LPA elicited platelet aggregation 
in whole blood in a time- and dose- dependent manner (Fig 5.12). Platelet aggregation started 
within 30 seconds and was irreversible. A concentration of 2.5 μM LPA induced already a 
significant aggregation response in whole blood. Maximum aggregation was reached with 20 μM 
LPA. 
5.3.3. 1-acyl-LPA (16:0) versus 1-alkyl-LPA (16:0) induced aggregation in 
whole blood 
When comparing the effect of 1- acyl-LPA (16:0) and 1-alkyl-LPA (16:0) on platelet aggregation 
in whole anticoagulated blood, the alkyl-LPA species was almost 20-fold more potent than the 
acyl-LPA species (Fig 5.13). 
The effective concentration causing 50% of maximum aggregation (EC50) for alkyl-LPA (16:0) 
was 0.3 μM versus 5μM for acyl-LPA (16:0). The lowest concentration that induced a significant 
platelet aggregation was 0.2 μM for alkyl-LPA (16:0) versus 2.5 μM for acyl-LPA (16:0) (P< 
0.01 and 0.001). 
1-acyl-LPA (16:0) and 1-acyl-LPA (18:1) demonstrated the same potency of platelet aggregation 
(results not shown).  
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Fig 5.13 
Dose response curves comparing the effect of 1-alkyl-LPA (16:0) and 1-acyl-LPA (16:0) in inducing platelet 
aggregation in whole blood  
Whole blood was stirred for 1 minute at 300 rpm at 37°C before either 1-acyl-LPA (16:0) or 1-alkyl-LPA (16:0) was 
added. Platelet aggregation was measured 5 minutes after addition of LPA. Values represent mean ±SD, n=4. 
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5.3.4. LPA- induced platelet aggregation in whole blood is independent of the 
type of anticoagulant 
Previous studies have shown that the type of anticoagulant can influence stimulus-induced 
platelet aggregation in whole blood. Therefore, we compared two types of anticoagulants, hirudin 
and citrate, and measured LPA-induced platelet aggregation in whole blood. In our experiments 
the type of anticoagulant used had no influence on LPA-induced aggregation. The time-course 
and concentration response curves of LPA-induced aggregation were similar in hirudin-and 
citrate-anticoagulated blood, indicating that the extracellular Ca2+ concentration was not critical 
for the aggregation response induced by LPA (Fig 5.14). 
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Fig 5.14 
Concentration response curve of LPA induced aggregation in blood anticoagulated with either citrate or hirudin 
Blood was anticoagulated with trisodium citrate (3.8% wt/v) or recombinant hirudin (200U/ml). LPA was added in 
different concentrations after 1 minute of stirring (300rpm) at 37°C. Aggregation was measured 90 seconds after 
adding LPA (mean ± SD, n=5). 
 
Similar than in PRP donor- dependent differences in aggregation could be observed in whole 
blood. In some donors platelets aggregated after addition of 2,5 μM of LPA. Also the maximum 
aggregation after adding 20 μM LPA was double in group A compared to group B (Fig 5.15).  
The distribution of the LPA- induced aggregation in blood is shown in Fig 5.16. Of 56 donors 
tested, 21 donors showed a platelet aggregation response to 20 μM LPA higher than 50 % with a 
mean ± SD of 70% ± 14 %. Others (25 donors) showed aggregation lower than 50 % with a mean 
± SD of 26 ± 14 %. Ten donors showed no significant aggregation as compared to control.  
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Fig 5.15 
Donor dependent differences in aggregation induced by different concentrations of LPA in LPA-sensitive donors 
Whole blood anticoagulated with hirudin was stirred for 1 minute at 300 rpm at 37°C before different LPA 
concentrations were added.  Group A represents donors that showed a maximum aggregation > 50%, group B lower 
than 50% after adding 20μM LPA. Values are mean ± SD, n=4 for group A, n=5 for group B. 
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Fig 5.16 
Distribution of LPA-sensitive donors in response to 20 μM of LPA 
Whole blood anticoagulated with hirudin was stirred for 1 minute at 300 rpm at 37°C before LPA was added. 
Aggregation was measured 90 seconds after the addition of LPA. Each dot represents % aggregation of one donor 
(n=56). Dotted line indicates the average spontaneous aggregation after stirring 90 seconds. 
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In order to measure the intra- individual variation of platelet aggregation, four donors were tested 
repeatedly (3 to 5 times) on different days and it was found that the aggregation response was 
fairly consistent within the same blood donor (Table 5.1). 
 
   Donor A       
Date  23.04.02 27.03.02 05.08.02 06.08.02 04.09.02  
Control      33         4        5        47       17 
LPA 20 μM       84       85       69         80                  76 
ADP 5 μM      84       78        78        82       85 
   Donor B       
Date  19.03.02 27.05.02 29.08.02 12.08.03    
Control      2  14        28        12           
LPA 20 μM      23   60        48       42               
ADP 5 μM      89  84        80        78         
   Donor C       
Date  25.02.02 04.03.02 05.03.02 07.03.02  
Control         14                    2         9         5        
LPA 20 μM      86         89          79        82        
ADP 5 μM      86             90        83         6          
   Donor D        
Date  18.09.03 02.04.02 25.04.02  
Control       3       16        16         
LPA 20 μM      46       27        35         
ADP 5 μM      75       59         84         
 
Table 5.1 
Aggregation induced by LPA in LPA-sensitive donors 
Whole blood anticoagulated with hirudin was stirred for 1 minute at 300 rpm at 37°C before LPA (20μM), ADP 
(5μM), or buffer was added. Different Donors (A- D) were tested on different dates. Values are shown in % 
aggregation.  
 
Spontaneous aggregation did not correlate with LPA-induced aggregation response (Fig 5.17), 
nor did the spontaneous aggregation correlate with ADP-induced aggregation (data not shown). 
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Fig 5.17 
Spontaneous aggregation vs. LPA- induced aggregation  
Whole blood anticoagulated with hirudin was stirred for 60 seconds at 300 rpm at 37°C in the presence of buffer 
(spontaneous aggregation) or LPA (10µM). Each dot represents % aggregation of individual donors (n=9). Shown 
here is the relationship between spontaneous and LPA-induced aggregation. 
Together these results show that the aggregation response to LPA in blood was dependent mainly 
on the blood donor.  
5.4. Mechanisms of LPA-induced platelet aggregation  
5.4.1. LPA-induced platelet aggregation in washed platelets and in PRP is 
partly mediated by secreted ADP 
5.4.1.1. Involvement of platelet ADP receptors 
In order to determine which mediators play a role in LPA-induced aggregation in washed 
platelets (prepared by method 3), the following antagonists were tested for their effectiveness in 
inhibiting aggregation.   
When the P2Y12 receptor antagonist, ARC-69931-MX, was added 1 minute prior to adding LPA 
(1 μM), the aggregation response to LPA was completely abolished. A similar inhibitory effect 
was seen after addition of the ADP-scavenging enzyme, apyrase. The P2Y1 receptor antagonist, 
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A3P5P, barely inhibited LPA-induced aggregation demonstrating a minor role. Results are shown 
in representative aggregation tracings (Fig5.18). 
In a control- experiment for ADP receptor specificity, platelet aggregation induced by ADP 
(5μM) was also inhibited by A3P5P (10 μM), AR-C69931MX (50 nM), and  
apyrase (5 U/ml).  
Platelets prepared according to method 3 appeared to be pre-activated (see section 5.1.2);  
therefore, method 4 of platelet preparation was used. With this method AR-C69931MX (P2Y12 
antagonist) as well as MRS2179 (P2Y1 antagonist) drastically reduced the LPA-induced 
irreversible platelet aggregation and converted it into reversible aggregation (Fig 5.19). A 
combination of both ADP receptor antagonists was only slightly more effective in inhibiting 
LPA-induced aggregation. This finding shows that ADP- mediated activation of the P2Y1 and 
P2Y12 receptor is required for LPA-induced secondary irreversible aggregation. 
Table 3a summarizes the effects of MRS2179, AR-C69931MX, and aspirin on LPA-induced 
aggregation and serotonin secretion in platelets prepared by method 4. The reduction of LPA-
induced aggregation of washed platelets was paralleled by the inhibition of serotonin secretion to 
less than 2% by AR-C69931MX, MRS2179, or a combination of both ADP receptor antagonists 
(Table 5.2a). Aspirin caused a reduction in serotonin secretion, but had no effect on platelet 
aggregation. 
  Buffer   Apyrase     AR-C69931MX  A3P5P  
   LPA   LPA     LPA   LPA 
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Fig 5.18 
LPA-induced aggregation is dependent on ADP-mediated activation of the P2Y12 receptor (in platelets washed by 
method 3) 
Platelets prepared according to method 3 were stirred for 1 minute at 1000 rpm and 37°C in the presence of P2Y1 
receptor inhibitor A3P5P (200 μM), P2Y12 receptor inhibitor AR-C69931MX (1μM), or apyrase (10 U/ml) before 
LPA was added. Tracings are representative of 6 experiments. 
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Fig 5.19 
LPA- induced aggregation is dependent on ADP-mediated activation of P2Y1 and P2Y12 receptors (in platelets 
washed by method 4) 
Platelets washed by method 4 were incubated with buffer, MRS2179 (100μM), AR-C69931MX (1 μM), or a 
combination of both before addition of 10 μM LPA. Serotonin secretion (percent of total) is indicated in brackets. 
 
Aggregation (A) and serotonin secretion (S)  
 
     Control   Aspirin 
     A (%)  S (%)  A (%)  S (%) 
 
Buffer     0  0.3±0.2 (3)  0  0.5±0.5 (3)  
LPA**, 10 µM   77 (2)   13 (2)  71 (2)  4.2 (2)  
AR-C69931MX + LPA, 10 µM 28 (2)  1.1 (2)  36 (2)  1.4 (2)  
MRS2179 + LPA, 10 µM  26 (2)  1.4 (2)  27 (2)  1.1 (2)  
AR-C69931MX + MRS2179 + LPA 19 (2)  1.5 (2)  20 (2)  1.8 (2) 
 
LPA, 30 µM    80±5  (3) 19±11 (3) 73±16 (3) 7.7±4.4 (3) 
AR-C69931MX + LPA, 30 µM 36±16 (3) 0.8±0.6 (3) 33±14  (3) 1.4±1.3 (3) 
MRS2179 + LPA, 30 µM  41±24 (3) 1.9±1.6 (3) 32±19  (3)  2.1±0.8 (3) 
AR-C69931MX + MRS2179 + LPA 22±11 (3) 0.8±0.6 (3) 20±12 (3) 1.0±1.4 (3) 
 
Table 5.2a 
Effect of ADP- receptor antagonists on LPA-induced platelet aggregation (A) and dense granule secretion (S) of 
washed platelets (method 4) 
Platelets washed by method 4 were pre- incubated with buffer or ASS (1mM) before MRS2179 (100μM), AR-
C69931MX (1 μM), or a combination of both were added. Platelets were stimulated with 10 μM and 30 μM 1-acyl- 
LPA (16:0). Values are mean ± SD (n), A% = aggregation, S% = secretion. 
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In addition to serotonin secretion from dense granules, LPA can also induce P- selectin 
expression, released from α–granules.  LPA (30 μM) induced P-selectin expression was inhibited 
by either one of the ADP-receptor antagonists. Both ADP- receptor antagonists together show no 
additional effect (Table 5.2b). Aspirin had no effect on aggregation, however, reduced secretion 
significantly in platelets washed according to method 4.  
 
P-Selectin Expression (P)  
 
      Control      Aspirin 
               P- Selectin  (MFI) 
 
LPA, 30 µM        73   85 
AR-C69931MX + LPA, 30 µM     47   60 
MRS2179 + LPA, 30 µM      50   62 
AR-C69931MX + MRS2179 + LPA      47   56 
 
Table 5.2b 
Effect of ADP- receptor antagonists on LPA-induced P-Selectin expression of washed platelets (method 4) 
Platelets washed by method 4 were pre- incubated with buffer or ASS (1mM) before MRS2179 (100μM), AR-
C69931MX (1 μM), or a combination of both were added. Platelets were stimulated with 30μM LPA. P% = P- 
Selectin expression was measured fluorescence of CD62p-FITC conjugated antibody, (n=1), MFI = mean 
fluorescence intensity.  
 
In order to test the effect of platelet inhibition in a more physiological medium we tested the 
same antagonists on LPA-induced aggregation in PRP.  
In PRP high and low responders were distinguished by the amplitude and reversibility of 
aggregation (Table 5.3). Irreversible aggregation, seen in the high responders to LPA, could be 
reduced and converted into reversible aggregation by either the P2Y1 or the P2Y12 receptor 
antagonist. Reversible aggregation could be inhibited significantly only by both ADP-receptor 
antagonists together. Remarkably Aspirin showed no inhibition of aggregation (Table 5.3). 
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     Aggregation in %       
     high responders  low responders 
LPA 80 µM        73±12 (12)       21±11 (8) 
ASS PRP + LPA        71±12 (7)           22±12 (8)                         
AR-C69931MX + LPA      38±10 (8)     
A3P5P + LPA        39±9 (12) 
Apyrase        40±13 (10) 
A3P5P + AR-C69931MX + LPA         14±12 (8) 
Table 5.3 
LPA- induced aggregation in PRP - effect of ADP receptor-antagonists and ASS 
PRP was pre – treated with Aspirin right after drawing blood. PRP was stirred for 1 minute at 1000 rpm at 37°C 
before LPA (80 μM) was added. High responders were donors from group 1 and low responders from group 2. ADP- 
receptor antagonists were added 15 seconds before LPA. Aggregation induced by ADP was set to 100%. Values are 
mean ± SD, n= 5-7. 
The aggregation and ATP secretion seen in Fig 5.10 (section 5.3.1) represents the aggregation 
response of low responders. Aggregation could be inhibited by the P2Y1 and P2Y12 - ADP 
receptor antagonists, A3P5P and AR-C69931MX. Aggregation was reduced slightly by either 
one of the ADP-receptor antagonists. Both receptor antagonists together inhibited aggregation 
and ATP secretion almost completely. ATP secretion was proportional to the amplitude of 
aggregation (Fig 5.10).  
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Fig 5.20 
LPA-induced secondary irreversible aggregation mediated by ADP 
PRP was stirred at 1000 rpm for 1 minute at 37°C in the presence of A3P5P (100μM), before addition of 80μM LPA 
to a high responding blood donor. Representative tracings are of one individual donor. 5 experiments with different 
donors were performed with the same results. 
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Irreversible platelet aggregation induced by 80 μM of LPA in high responders (Fig 5.20) was 
converted into reversible aggregation by apyrase, the P2Y12 receptor antagonist AR-C69931MX, 
and the P2Y1 -receptor antagonist A3P5P. The P2Y1 -receptor antagonist MRS2179 had the same 
effect. 
These results indicate that LPA- induced irreversible aggregation was dependent on ADP, 
whereas LPA- induced reversible aggregation and secretion of low responders was mainly 
mediated by ADP activation of both, P2Y1  + P2Y12 , receptors. 
5.4.1.2. No inhibition of LPA- induced aggregation by aspirin in PRP and washed platelets 
Aspirin (1 mM) incubated for 10 minutes, did not inhibit LPA-induced irreversible or reversible 
aggregation, but reduced ATP secretion in PRP, (Table 5.3, Fig 5.21). Also no inhibition of 
aggregation, but a reduction of ATP secretion by aspirin was observed in washed platelets 
(method 4) (Table 5.2).  In platelets washed according to method 3, aspirin had no effect on LPA- 
induced aggregation as well (Table 5.4). The results indicate that cyclooxygenase dependent 
pathways, like thromboxane A2 (TX A2) production, do not play a role in LPA- induced 
aggregation (see Fig 5.12) 
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Fig 5.21 
Effect of aspirin on LPA-induced aggregation and ATP secretion of PRP 
PRP was incubated for 10 minutes with aspirin (1 mM) and stirred for 1 minute at 1000 rpm at 37°C before LPA 
(80μM) was added. Aggregation (% light transmission) and simultaneous ATP secretion were recorded in a Lumi-
aggregometer.  
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5.4.1.3. Role of intracellular Ca2+ 
The cytosolic Ca2+ chelator, BAPTA-AM, inhibited the LPA- induced aggregation completely in 
platelets washed by method 3. Similarly, the Ca2+ channel blocker, SKF 96365, could also inhibit 
the LPA-induced aggregation completely, indicating that LPA-induced aggregation in this type of 
washed platelet preparation is dependent on the influx of external Ca2+. The solvent control 
(DMSO) did not influence aggregation (Fig 5.22). 
LPA +   LPA +    LPA + 
DMSO   BAPTA – AM   SKF 96365 
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Fig 5.22 
LPA- induced aggregation of platelets (washed by method 3) is Ca2+ -dependent 
Platelets prepared according to method 3 were pre-incubated with DMSO (0.3%), BAPTA-AM (20 μM, dissolved in 
DMSO) for 20 min, or SKF96565 (100μM) for 10 min at 37°C before stirring for 1 minute at 1000 rpm and exposure 
to LPA (1 μM). Representative tracings of 5 experiments. 
 
Table 5.4 shows a summary of the effect of all platelet inhibitors on LPA- induced platelet 
aggregation using three different methods of platelet preparation. Activation of the P2Y12 and 
P2Y1 receptors seem to be involved in irreversible aggregation, whereas Ca2+ is essential for 
reversible aggregation.   
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   Platelets  Platelets  PRP  
washed by   washed by  
method 3  method 4 
 
   LPA 1 μM  LPA 30μM  LPA 80 μM 
 
Buffer       ++       ++       ++ 
Aspirin, 1mM      ++        ++       ++  
Apyrase, 10U/ml      +        +        + 
MRS 2179, 100μM      +          +        + 
A3P5P, 100μM      +                + 
AR-C69931, 1μM      +        +        + 
EGTA, 5 mM        -               - 
BAPTA- AM, 200μM      -    
SKF 96365       -                - 
 
 
Table 5.4 
Summary showing the effect of platelet inhibitors on LPA-induced platelet aggregation of washed platelets (method 
3 and method 4) and PRP 
(++ ) indicates secondary aggregation (irreversible), ( + ) indicates primary aggregation (reversible), and ( - ) shows 
no aggregation.   
5.4.2. Mediators of LPA -induced aggregation in whole blood 
5.4.2.1. Dependency on platelet ADP receptors, but not thromboxane formation  
Platelet aggregation in whole blood stimulated by LPA was entirely dependent on ADP- induced 
activation of the P2Y1 and the P2Y12 receptor as determined by the use of the ADP-scavenging 
enzyme apyrase and specific ADP receptor antagonists (Table 5.5, Fig 5.23). 
 
The ADP receptor antagonists, AR-C69931MX and MRS2179 inhibited LPA-induced 
aggregation below baseline (buffer-stirred control) (Fig 5.23). As a control for ADP receptor 
specificity, platelet aggregation induced by ADP was also inhibited by MRS2179 and AR-
C69931MX (Table 5.5). Notably, also in whole blood aspirin did not inhibit LPA-induced 
aggregation.  
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Fig 5.23 
LPA- induced aggregation is completely inhibited by blocking either P2Y1 or P2Y12 receptor and is insensitive to 
inhibition by aspirin 
Whole blood anticoagulated with hirudin was pre-incubated for 10 minutes at 37°C with aspirin (1mM) and/or stirred 
for 1 minute at 300 rpm in the presence of AR-C69931MX (1μM) and MRS2179 (100μM) before addition of 10μM 
LPA. Aggregation was measured at various times after adding LPA (mean ± SD, n=3). 
 
Platelet aggregation, % 
     control  LPA2 20 µM  ADP 5 µM 
Buffer     18±12  (6) 72±26 (6)  89±18 (6) 
Aspirin1    ------------ 72±13 (5)  ------------ 
Apyrase1     ------------ 17±11 (6)*  ------------ 
AR-C69931MX 1   ------------ 7±3 (3)**  15±12(6)* 
MRS21791    ------------ 9±5 (3)**  28±16(6)* 
AR-C69931MX + MRS21791    10±4 (6)**  13±6 (6)** 
RGDS1    ------------ 19±9 (6)*  ------------ 
Anti-P-selectin1    ------------ 61±14 (4)  ------------ 
 
Table 5.5 
Effect of platelet inhibitors on LPA-and ADP-induced platelet aggregation in whole blood 
Concentrations of platelet inhibitors1 were aspirin 1 mM, AR-C69931MX 1 μM, MRS2179 100 μM, RGDS 5 mM, 
apyrase 10 U/ml, and anti-P-selectin 10 μg/ml. -------- indicates that these values have not been determined. Values 
are mean ± SD, (number)=n. 
* P< 0.05  ** P<0.01. 
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5.4.2.2. No role of the Ca2+  dependent pathway in whole blood 
Platelet aggregation was not significantly inhibited by the Ca2+ channel blocker, SKF96365, nor 
by the external Ca2+ chelator EGTA (Table 5.6). 
 
Control       36 +/- 19 (4) 
LPA       52 +/-9 (4)  
EGTA1  + LPA     61 +/-18 (4)   
SKF 963651  + LPA     49 +/- 19 (4)   
EGTA+ SKF1  + LPA     66 +/- 20 (4)   
Table 5.6 
Effect of Ca2+ inhibitors on LPA- platelet aggregation in whole blood 
Concentrations of platelet inhibitors1 were SKF96365 100 μM (incubated for 5 minutes), and EGTA 5 mM (added 
10 seconds before LPA, 20μM, addition). Values are mean ± SD (n). 
 
5.4.2.3. LPA-receptor desensitization inhibits LPA- induced aggregation 
To determine whether the LPA- induced aggregation was mediated by LPA- receptor activation, 
desensitization experiments were performed in whole blood. LPA (10 μM) was incubated for 10 
minutes at 37°C followed by stimulation with LPA (20 μM) or other agonists, ADP (5 μM) and 
collagen (0.5 μg/ml). Platelet aggregation was diminished with subsequent LPA stimulation, but 
not with addition of ADP (Table 5.7).  
 
Agonist 
Pre-Ink 10’ LPA  
+ buffer 
Pre-Ink 10 ‘ LPA 
 + LPA 
Pre- Ink 10’ LPA 
 + ADP 
Pre-Ink 10 ‘ LPA 
 + Collagen 
 
Agg % 12 +/- 4  23 +/-2 70 +/-5 79 +/-2 
Agonist 
Pre-Ink 10’ buffer  
+ buffer 
Pre-Ink 10’ buffer 
+ LPA  
Pre-Ink 10’ buffer 
 + ADP  
Pre-Ink 10’ buffer
 + Collagen 
Agg % 16 +/- 9 40 +/-7 71 +/- 10  77 +/-2 
 
Table 5.7 
LPA-receptor desensitization inhibits LPA-induced platelet aggregation in whole blood 
Samples anticoagulated with hirudin were incubated at 37°C with 10 µM LPA (upper row) or with buffer (lower 
row). After 10 minutes either buffer, LPA 20 µM, ADP 5µM, or collagen 2.5 µg/ml, were added. Aggregation was 
measured after 90 seconds, (mean ± SD, n=3). 
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Interestingly, incubation of blood for 10 min at 37ºC reduced the LPA-induced aggregation, but 
not the ADP- induced aggregation.  
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Fig 5.24 
Incubation of blood at  37°C inhibits LPA- induced platelet aggregation in whole blood 
Whole blood samples anticoagulated with hirudin were incubated at 37°C for 1 min (control) or 10 min. Then either 
buffer, LPA 20 µM, or ADP 5µM were added and aggregation was measured 1 minute after addition of the agonist 
(mean ± SD, n=6). 
5.5. LPA synergizes with different platelet stimuli in inducing 
platelet aggregation in washed platelets and whole blood 
Based on the fact that dose-response curves of LPA for platelet shape change and aggregation in 
blood were similar (compare Fig 5.8a and Fig 5.12), we hypothesized that LPA stimulates signal 
transduction pathways during platelet shape change that synergize with signalling pathways 
stimulated by other agonists leading to platelet aggregation in whole blood. It has been shown in 
the past and rediscovered recently that upon coactivation of platelet receptors that couple to 
different G proteins, their specific signal transduction pathways converge in inducing platelet 
aggregation (Dorsam et al., 2002; Nieswandt et al., 2002; Quinton et al., 2002). 
LPA is known to activate in various cell types proteins of the G12/13 family that couple to the 
Rho/Rho-kinase pathway. In platelets it is likely that only G13 will be activated by LPA, since 
G12, albeit expressed in mouse platelets, is not functional (Moers et al., 2003). In the present 
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study we investigated whether LPA might also induce the activation of Gi that leads to a decrease 
in cAMP levels in platelets.  
Base value 
without Iloprost 18 9 12 40 19
Iloprost 50 nM 100 100 100 100 100 100 100 100
LPA 0.1μM 118 114 44 87 78 100 88 90 ± 25
LPA 0.5μM 94 44 95 100 91 85 ± 23
LPA 1 μM 112 165 100 87 117 73 72 102 ± 32
LPA 5μM 71 86 12 73 84 65 ± 30
LPA 10 μM 94 78 24 100 48 40 63 64 ± 28
LPA 20 μM 116 77 70 72 84 ± 22
LPA 40 μM 94 104 48 107 116 40 83 ± 32
LPA 80 μM 93 91 40 75 ± 30
ADP  5 μM 47 23
ADP 50 μM 65 24 59 91 40 24 50 ± 26
Epi 10 μM 12 10 12 20 12 49 24 21 ± 14
Experiment 
1 2 3 4 5 6 7 mean±
 
  
 
  
  
SD
 
Table 5.8 
cAMP in % of the initially raised cAMP levels with prostacyclin analogue Iloprost 
Samples from platelets isolated by method 1 incubated in the presence of Iloprost 37°C for 5 minutes in order to raise 
cAMP levels. Platelets were then stirred at 1000 rpm for 30 seconds until the platelet stimulant, LPA (0.1 – 80 μM), 
ADP (5 and 50 μM) or epinephrine (10 μM) was added. Values (in % of initially raised cAMP) are measured in 
duplicates, mean ±SD (n). 
 
  Aggregation, % 
Buffer          4±4 (4) 
LPA, 20 µM       14±11 (4) 
ADP, 0.5 µM        26±12 (4) 
LPA + ADP        74±10 (4) 
 
 
Table 5.9 
LPA synergizes with ADP in inducing platelet aggregation in whole blood 
Samples anticoagulated with hirudin, incubated at 37°C and stirred for 1 min, were stimulated by LPA (20μM) or 
ADP (0.5μM) alone or in combination. Values are mean ±SD (n). 
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Levels of cAMP in unstimulated platelets were raised from 8 ± 1 pmol /108 platelets (n=5) to 54 ± 
24 pmol / 108 platelets (n=7) by the prostacyclin analogue iloprost. In platelets treated with a 
large concentration range of LPA (0.1-80 μM) there was no significant change in the 
concentration of cAMP (n=7), whereas epinephrine (10 μM) showed a decrease in cAMP to 10 ± 
5 pmol/ 108 platelets (n=7), respectively. Therefore, platelet LPA receptors are unlikely to couple 
to Gi. We also have previously obtained evidence that LPA receptors activated during shape 
change do not couple to Gq (Maschberger et al., 2000). Therefore, the only G protein activated by 
LPA during shape change seems to be G13.
Next, we investigated whether LPA receptor-coupled G13 activation might synergize with other 
platelet receptors that couple to Gi or Gq in inducing platelet aggregation. Stimulation of washed 
platelets by LPA together with epinephrine, known to selectively activate Gi in platelets, or 
together with ADP, activating Gi through P2Y12 receptor, synergistically induced platelet 
aggregation (Fig 5.25a,b) 
Moreover, also LPA and serotonin, which selectively stimulates Gq and subsequent Ca2+ 
mobilization in platelets, synergized in inducing platelet aggregation (Fig 5.25c). Interestingly, 
the synergistic platelet aggregation of LPA plus serotonin, but not of LPA plus epinephrine, was 
inhibited by the ADP receptor antagonists, indicating different dependency of the aggregation 
response on released ADP (Fig 5.25b-c). We also observed that LPA synergized with ADP, 
epinephrine, and serotonin in inducing platelet aggregation in blood (Table 5.8 and data not 
shown). 
To explore the signal transduction pathway stimulated by LPA receptor G13 activation that 
underlies the synergism, we studied the involvement of the Rho /Rho kinase pathway, which is 
known to mediate LPA-induced shape change in washed platelets.  
Although LPA-induced shape change in whole blood was blocked by pre-treatment with the Rho 
kinase inhibitor Y-27632 (Fig 5.7b), aggregation induced by LPA plus low concentrations of 
ADP (0.5 and 1 μM) in blood was not inhibited by Y-27632, excluding a role of the Rho/Rho 
kinase pathway in the synergistic aggregation response (Fig 5.26).  
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Fig 5.25a,b,c 
LPA synergizes with ADP, epinephrine, and serotonin in inducing aggregation of washed platelets (method 4)  
Washed platelets were stimulated by LPA, epinephrine (ADR), or serotonin (5-HT) alone or in combination. The 
synergistic aggregation induced by LPA plus serotonin, but not LPA plus epinephrine was inhibited by MRS2179 or 
AR-C69931. 
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Fig 5.26 
LPA– induced aggregation in synergy with ADP- was not inhibited by the Rho kinase inhibitor Y27632  
in whole blood 
Whole blood anticoagulated with hirudin, incubated at 37°C and stirred for 1 min, was stimulated by LPA (20μM) in 
combination with  ADP (0.5μM) or ADP (1.0μM). Samples were incubated for 30 min at 37°C with the Rho kinase 
inhibitor, Y27632 (20μM). Values are mean ±SD, n = 3. 
5.6. Role of LPA produced by platelets in thrombin- or collagen- 
stimulated platelet aggregation  
LPA produced by thrombin or collagen- aggregated platelets might play a role as a positive 
feedback mediator of platelet activation. Washed platelets produce about 5 ng LPA/ 109 cells after 
aggregation with thrombin (2 U/ml) for 2 minutes that will lead to a maximal concentration of 10 
nM LPA assuming a complete release of LPA from platelets to the extracellular medium (Gerrard 
and Robinson, 1989). 
With the aim of analyzing the possible role of endogenous LPA as a positive feedback loop for 
aggregation, washed platelets (method 4) were pre-treated with the LPA- receptor antagonist 
NPSerPa and then stimulated with different concentrations of collagen and thrombin. NPSerPa 
(10 μM), which completely blocked shape change induced by 0.1 to 0.5 μM LPA (data not 
shown), had no effect on thrombin- or collagen – induced platelet aggregation (Table 5.10). 
These results indicate that LPA formed by activated platelets does not mediate or support 
stimulus- induced platelet aggregation. 
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      Aggregation, % 
      Control NPSerPA  
 
Collagen, 1 µg/ml    85±9 (4) 60±30 (4) 
Collagen, 2.5 µg/ml    80±6 (4) 86±16 (4) 
Thrombin 0.1 U/ml    67±23 (4) 68±27 (4) 
Thrombin 0.2 U/ml    88±16 (4) 89±12 (4) 
 
Table 5.10 
Effect of the LPA-receptor antagonist NPSerPA on collagen- and thrombin- induced aggregation of washed platelets 
Washed platelets (0.4 ml) prepared according to method 4 were pre-incubated with albumin (0.25 mM)-buffer (12μl, 
control) or NPSerPA (10 µM) for 10 min at 37 °C before stimulation with collagen or thrombin.  Aggregation was 
measured 2 min after addition of the stimuli. 
5.7. LPA- induced platelet-monocyte interaction  
Platelet-monocyte interaction was measured by flow cytometry in counting the number of 
monocytes that were positive for FITC-labelled platelet marker CD 41a, thus recording the 
number of monocytes with adherent platelets as a percentage of all monocytes. 
The graph below shows the right shift of the curve in response to 20 μM of LPA. The degree of 
right shift is about equal to the degree of shift seen after the addition of a strong agonist, such as 
collagen. 
IgG1 Isotype Control
Buffer Control, stirred LPA 20 µM
 
Fig 5.27 
Gated monocytes with increasing CD41a-PE indicate platelet adhesion to monocytes  
Increasing fluorescence-1 (right shift) indicates the increasing occurrence of CD41a-PE on monocytes. Blood 
samples were stirred for 5 minutes 300 rpm 37°C after addition of buffer or LPA (20μM). 
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5.7.1. Mechanism of LPA-induced platelet-monocyte aggregate formation 
LPA (20 μM) stimulated the formation of platelet-monocyte aggregates in anticoagulated blood 
from 32% ± 13.5% (control, stirred samples) to 89% ± 19% (mean ± SD, n= 13, Fig 27). A 
similar increase was seen after addition of 5 μM ADP, 72% ± 31% (values are mean ± SD, 
n=11). 
The stimulation of platelet-monocyte aggregate formation was dose- dependent (Fig 5.27a). 
Platelet-monocyte aggregate formation was significantly increased after 2.5 μM LPA and was 
maximal after 20 μM LPA, 87% ± 12% (Fig 5.27a).  
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Fig 5.27 
LPA- induced platelet- monocyte aggregate formation is dose-dependent and P-selectin mediated 
a) dose response curve of LPA-induced platelet-monocyte aggregate formation  
Platelet-monocyte aggregates in stirred blood samples at 300 rpm 37°C were measured 5 minutes after incubation 
with LPA by FACS analysis. Values represent the mean ± SD, n=7-19, *P<0.05 **P<0.01. 
b) Platelet-monocyte aggregate formation is mediated via P-selectin  
Effects of ADP receptor antagonists and aspirin. Blood samples were stirred for 5 minutes 300 rpm 37°C after 
addition of buffer or LPA (20μM). A blocking anti-P-selectin antibody (10 μg/ml) or the ADP- receptor antagonists 
MRS2179 (100 μM) and AR-C69931 (1 μM) alone or in combination was added 30 seconds before the addition of 
buffer or LPA. Blood was incubated with aspirin (1 mM) for 30 to 45 minutes prior to treatment with LPA. Values 
represent mean ± SD, n=8-10. *P<0.05 as compared to control. 
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Pre-incubation with a blocking P-selectin antibody completely inhibited LPA-induced platelet-
monocyte aggregate formation. These results indicate that platelet-monocyte aggregate formation 
in LPA-stimulated platelets is mediated by P-selectin, an adhesion molecule that is expressed on 
the platelet surface upon platelet activation. LPA-induced platelet aggregation was not inhibited 
(Table 5.5, section 5.4.2), indicating, firstly, that P-selectin antibody did not unspecifically inhibit 
LPA-induced platelet activation and, secondly, that platelet aggregation was not required for 
platelet-monocyte conjugate formation. 
The P2Y1 receptor antagonist MRS2179 (100 μM) and the P2Y12 receptor antagonist AR-
C69931MX (1 μM), did not significantly inhibit the LPA-induced platelet-monocyte aggregate 
formation in whole blood (Fig 5.27b). Only both ADP- receptor antagonists together significantly 
reduced the LPA-induced platelet-monocyte aggregate formation (p<0.05), indicating that the 
concomitant stimulation of both ADP- receptors plays a role in the LPA- induced platelet- 
monocyte adhesion.  
Partially supporting these results is the fact that in washed platelets (method 4), we observed an 
inhibition of P-selectin expression by either one of the ADP-receptor antagonists. But no 
additional inhibition could be seen by the combination of both ADP-receptor antagonists in 
washed platelets stimulated by LPA (30μM) (section 5.4.1, Table 2b).  
The fibrinogen receptor antagonist RGDS (5 mM) completely inhibited LPA- induced platelet 
aggregation (Fig 5.28 and Table 5.4, section 5.4.1), but not platelet- monocyte aggregate 
formation (66% ± 26% versus 68% ± 35%, mean ± SD, n=9). The basal levels of platelet- 
monocyte aggregates were even enhanced after RGDS (59% ± 30% versus 32% ± 13%, n=8, P < 
0.05) (Fig 5.28). 
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Fig 5.28 
LPA- induced platelet- monocyte aggregate formation is not inhibited by RGDS 
Platelet-monocyte aggregates in stirred blood samples at 300 rpm 37°C were measured 5 minutes after incubation 
with LPA. The fibrinogen receptor antagonist, RGDS (5mM) was added 30 seconds prior to LPA. Values represent 
the mean ± SD, n=9. 
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Platelet- monocyte formation could also be inhibited by EGTA 5 mM. EGTA was added just 
prior to LPA (20 μM) to avoid any alteration of the GP IIb/ IIIa fibrinogen receptor. Platelet 
aggregation, which is dependent on a functional fibrinogen receptor, was not inhibited by EGTA 
in the same samples (Table 5.11).  
EGTA (5 mM) inhibited the LPA-induced platelet-monocyte formation significantly, resulting in 
a reduction from 52 ± 9 % to 17 ± 13 %. SKF 96365 (100 μM) also showed a reduction of LPA-
stimulated platelet-monocyte-conjugate formation; however, this effect was non-significant 
(Table 5.11).  
 
Stirred control 
sample 
LPA EGTA + 
LPA 
SKF + 
LPA 
EGTA + SKF +
LPA 
28 +/- 5 52 +/- 9 17 +/- 13 ** 34 +/- 15 27 +/- 20* 
  **p> 0.005   * p< 0.05 
Table 5.11 
Inhibition of platelet- monocyte aggregation by the external Ca2+ chelator EGTA and or the Ca2+ entry inhibitor SKF 
96365 
Platelet-monocyte aggregates in stirred blood samples at 300 rpm 37°C (anticoagulated with hirudin) were measured 
5 minutes after incubation with 1-acyl-LPA (16:0). The external Ca2+ chelator, EGTA 5 mM, was added 10 seconds 
before the addition of buffer or LPA, the Ca2+ channel blocker SKF 96365 was incubated for 5 minutes at 37°C prior 
to LPA addition. Values represent mean ± SD (n=4). 
 
% Platelet- monocyte aggregation 
                                    Donors  
   A  B  C 
Experiment 1  84  53  92 
Experiment 2  52  71  96 
Experiment 3  95  58  92 
Experiment 4  69    70 
 
 
Mean   75  61  88 
± SD   19  9  12 
 
Total mean ± SD   75± 16 (n=11) 
 
Table 5.12 
Inter – and intra- individual variations of platelet- monocyte aggregation induced by LPA 
Platelet-monocyte aggregates in stirred blood samples, 300 rpm at 37°C, were measured 5 minutes after incubation 
with LPA by FACS analysis. Blood of individual donors (A-C) 1 was tested in different experiments. Values are 
mean ±SD, n= 3-4. 
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Pre-incubation of whole blood with aspirin (1mM) did not inhibit the LPA-induced platelet-
monocyte aggregate formation (Fig 5.27b). Under the same conditions aspirin reduced the 
collagen (0.1µg/ml)-induced platelet aggregate formation significantly (n=8, p<0.05), indicating 
that the treatment with aspirin was effective. Aspirin was also found to be ineffective in inhibiting 
P-selectin exposure of washed platelets stimulated by LPA (section 4.4.1, Table 5.2b). 
Whereas LPA-induced platelet aggregation in blood was donor-dependent, we observed that 
platelet- monocyte aggregate formation was not. Variations observed were non- donor- specific, 
shown in Table 5.12.  
5.7.2. Specific desensitization of the LPA-receptor mediated platelet- monocyte 
aggregate formation in whole blood 
Similarly to the results shown for LPA-induced platelet aggregation, LPA-stimulated platelet- 
monocyte aggregate formation could be specifically desensitized by incubating the samples with 
10 μM LPA for 10 minutes. The LPA desensitized sample showed a platelet- monocyte 
aggregation which is close to the baseline (Table 5.13, results shown in bold), whereas the sample 
incubated with buffer still showed a significant platelet- monocyte aggregation after stimulation 
with LPA. 
Stimulation with collagen or ADP of the LPA-densitized sample, showed no inhibition of 
platelet-monocyte formation, demonstrating the specific desensitization of the LPA-receptor 
(Table 5.13). 
 
Agonist 
Ink 10’LPA 
 + buffer 
Ink 10 ‘ LPA 
 + LPA 
Ink 10’ LPA +
ADP 
 Ink 10 ‘ LPA 
 + Collagen 
 
platelet-
monocytes, % 34 +/- 5  35 +/- 6 90 +/-5 93 +/-3 
Agonist 
Ink 10’ buffer +
buffer 
Ink 10’ buffer 
 + LPA  
Ink 10’ buffer 
+ ADP  
Ink 10’ buffer  
+ Collagen 
Platelet-
monocytes, % 27 +/- 6 50 +/-16 73 +/- 16  96 +/-1 
Table 5.13 
Specific desensitization of LPA- induced platelet monocyte aggregate formation 
Samples were incubated at 37°C with 10 µM LPA (row 1) or with buffer (row 2). After 10 minutes either buffer or 
the agonist, LPA 20µM, ADP 5µM, or collagen 2.5µg/ml, were added. Platelet-monocyte aggregates in stirred blood 
samples were measured 5 minutes after the addition of LPA by FACS analysis (mean ± SD, n=3). 
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6. Discussion 
6.1. LPA induced shape change in washed platelets, PRP, and whole 
blood 
We observed that about a 500-fold lower LPA concentration was required for platelet shape 
change in isolated platelets compared to that in PRP. From the several LPA- binding proteins 
albumin is the major plasma protein responsible for the inhibition of LPA-induced shape change 
(Fig 5.6). The action of LPA was reported to be inhibited by albumin in sf9 insect cells 
expressing specifically the LPA3 receptor (Hama et al., 2002). Thus albumin blocking LPA-
induced shape change in isolated platelets implies that LPA-induced shape change could be LPA3 
mediated. Such a conclusion would be consistent with results applying the LPA-receptor 
antagonist, 8:0 -diacyglycerolphosphate (DGPP). DGPP (8:0) has a higher affinity for the LPA3 
receptor than the LPA1 receptor and inhibits platelet shape change induced by LPA (Rother et al., 
2003). 
Since plasma was more potent than albumin in inhibiting LPA-induced shape change (Fig 5.6), 
other LPA-binding proteins in plasma, such as gelsolin, were suspected to have an additional 
inhibiting effect. However, no inhibition was seen with gelsolin. In a previous study by Goetzl et 
al., gelsolin concentrations of less than 10% of the plasma concentration were shown to increase 
LPA activity, whereas 20% or higher concentrations of those in plasma diminished biological 
effects of LPA in rat cardiac myocytes (Goetzl et al., 2000). In this study LPA-induced gene 
activation was measured which required much longer incubation times (24-30 hours) (Goetzl et 
al., 2000) than in the present study measuring LPA- induced platelet activation (15-30 sec). The 
longer incubation time may have been necessary to allow for effective LPA-gelsolin binding. It is 
also possible that LPA in our experiments could not readily bind to gelsolin, since both 
substances were added almost simultaneously to platelets. Another possible explanation is the 
fact that Goetzl et al. has shown by western blot analysis that only LPA1 and LPA2 receptors are 
expressed in rat cardiac myocytes. If shape change would be LPA3-mediated, as proposed earlier, 
this receptor may not be influenced by gelsolin-delivered LPA. Therefore, it still remains open 
which plasma factors in addition to albumin inhibit LPA-induced shape change. 
The dose-response curves for LPA- induced platelet shape change in PRP and blood were almost 
identical, indicating that platelet stimuli possibly released from blood cells, such as ADP from red 
cells, did not synergize with LPA in inducing platelet shape change in blood. Moreover, the LPA-
induced shape change in blood was not inhibited by ADP receptor antagonists showing 
independence of a synergy with ADP and implying a direct LPA-receptor mediated activation. In 
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PRP and blood LPA-induced shape change could be inhibited by the Rho-kinase inhibitor 
Y27632, indicating that the G13 pathway leading to Rho activation was also required for platelet 
shape change in blood as previously shown for platelets in suspensions (Bauer et al., 1999; Retzer 
et al., 2000). The fact that dose-response curves for shape change and aggregation in whole blood 
were similar suggests that analogous signaling pathways were activated by LPA in PRP and 
blood.  
6.2. Platelet aggregation in washed platelets, PRP, and whole blood 
6.2.1.Difference in aggregation using different isolation procedures of washed 
platelets 
The principle advantage of isolating platelets is that platelets can be studied in the absence of red 
blood cells and plasma proteins, which could influence platelet activation. In addition platelets 
can be prepared in large quantities and the platelet concentrations and divalent cations (Ca2+, 
Mg2+) can be adjusted to physiological levels.   
LPA induced the initial platelet response, shape change, in washed platelets prepared by method 
1 and method 2. Platelets, however, did not aggregate in response to low (5μM) or very high (120 
μM) LPA concentrations. Even the addition of fibrinogen (0.1-1 mg/ml), plasma (2-20 %), Ca2+ 
(1mM), alone and in combination of both or all three, did not enable platelet aggregation in 
response to LPA. Methods 1 and 2 use two washing steps and apply ADP scavengers, apyrase, or 
CP/ CPK. 
Platelets prepared according to method 3 showed irreversible platelet aggregation, which was 
observed after low concentrations of LPA (1μM). In method 3 no washing step and no ADP 
scavengers were used. It is likely that by using this method, LPA synergized with ADP in 
inducing aggregation as observed previously (Benton et al., 1982; Gueguen et al., 1999). ADP 
can be released during platelet centrifugation and by resuspending the platelet pellet. Indeed, 
when the P2Y12 receptor antagonist, ARC-69931-MX, or apyrase was added, the aggregation 
response to LPA was completely abolished indicating that the ADP-induced P2Y12 activation 
mediates the synergistic effect with LPA in this platelet preparation. The P2Y1 receptor 
antagonist, A3P5P, did not inhibit LPA-induced aggregation. It has been shown that the P2Y1 
receptor, but not the P2Y12 receptor is desensitized after exposure of platelets to ADP (Gachet, 
2000). Thus a possible explanation is that the P2Y1 receptor is already desensitized during platelet 
preparation by method 3 due to the release of ADP during platelet centrifugation and 
resuspension.   
By the fact that no shape change was seen and platelets lost their reactivity after 30- 60 minutes, 
we can further conclude that these platelets were pre-activated possibly due to the ADP release. 
In a method similar to method 3 Benton et al used only one centrifugation step to obtain the 
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platelet pellet and excluded the use of apyrase (Benton et al., 1982; Gueguen et al., 1999). They 
were the first to show LPA-induced platelet shape change and aggregation in washed platelets. 
However, they used acid citrate dextrose (ACD) anticoagulated blood, followed by dilution with 
ACD to PRP in a 1:1 ratio, thus chelating much more of the extracellular Ca2+ and Mg2+, than in 
our method 3, and thereby possibly preventing platelet pre-activation during the subsequent 
centrifugation step.  
Platelets prepared according to method 4 were not pre-activated and showed shape change 
followed by aggregation in response to LPA. The reaction of platelets to LPA using this method 
was similar to platelet activation in PRP. The platelets were washed in the presence of 
prostacyclin (PGI2) and heparin and resuspended in buffer containing apyrase to avoid 
desensitization of the ADP receptor P2Y1 (Baurand et al., 2000; Cazenave et al.). PGI2 prevents 
dense granule release during centrifugation. No dense granule secretion as measured by serotonin 
release occurred until platelets were stimulated by LPA. LPA in this platelet preparation caused 
irreversible aggregation via ADP release from dense granules. This can be concluded by the 
inhibition of LPA-induced platelet aggregation by either ADP-receptor antagonist (Fig5.19). 
6.2.2. Aggregation in PRP and whole blood 
LPA induced platelet aggregation in whole blood at very low concentrations approaching those 
found in vivo (0.5- 1μM) (Fig 5.12) (Baker et al., 2000). In comparison much higher LPA 
concentrations were required in platelet rich plasma (Fig 5.9). Therefore, we suspected platelet 
stimulating factors to be present in whole blood. Using different platelet inhibitors for studying 
the possible mechanism we found that blockade of either the P2Y1 or the P2Y12 receptor 
completely inhibited LPA-induced platelet aggregation in whole blood, demonstrating a complete 
dependence on ADP possibly released from red blood cells or from platelets. LPA on its own 
induced very little dense granule secretion (1-2%) in washed platelets, but LPA together with 
ADP, once secreted, effectively induced dense granule release. Remarkably, blockade of either 
the P2Y1 or the P2Y12 receptor reduced LPA-induced dense-granule secretion. Our results 
indicate that coactivation of the LPA-receptors with either one of the two purinergic ADP 
receptors is sufficient to induce full platelet response. Both ADP receptors show equal 
importance in mediating LPA-induced aggregation in whole blood (Fig 5.23) and aggregation 
and dense granule secretion of washed platelets (method 4) (Fig 5.19). Most likely both ADP 
receptors are activated simultaneously by released ADP, and the synergism of signaling pathways 
induced by the P2Y1 receptor (Gq, Ca2+) and the P2Y12 receptor (Gi) is required for platelet 
aggregation. Indeed, exogenous ADP also induces platelet aggregation in whole blood which is 
blocked by either P2Y1 or P2Y12 inhibition (Table 5.5). The situation is different for ADP-
induced platelet activation in suspensions or PRP, where the P2Y1 receptor has been responsible 
for the initial activation and the P2Y12 receptor for amplification (Storey et al., 2001).  
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In the presence of ADP receptor antagonists washed platelets (method 4) still showed a small 
aggregation in response to LPA, whereas platelets in blood show no aggregation. This may either 
be due to the inhibition of LPA by albumin present in blood or due to a faster degradation of 
LPA, possibly via the ectoenzymes LPP1 and LPP2 expressed on blood cells.  
Platelets in whole blood and PRP showed different LPA- aggregation responses according to the 
blood donor (Fig 5.9, Fig 5.15, Fig 516, Table 5.1), whereas shape change, induced by direct 
LPA-receptor activation was similar in all donors. This indicates that the different aggregation 
responses of individual donors are not due to different binding of LPA to its receptors, or 
activation of platelet LPA receptors. Thus, donor-dependent variations in the concentration of 
albumin which binds LPA, are unlikely to explain the different LPA aggregation responses. The 
difference is also unlikely to be explained by environmental and endogenous factors, such as age, 
cigarette smoking, alcohol consumption, and dietary fat, that have been shown to influence inter- 
individual variability in aggregation responses to other platelet stimuli (Mori et al., 1997; Renaud 
et al., 1992; Terres et al., 1989; Terres et al., 1991). No correlation between these factors and 
platelet aggregation could be seen in our donors. 
Since LPA-induced aggregation in blood was completely and in PRP partly dependent on the 
synergism with released ADP, it is possible that platelets from LPA-responsive donors could 
have a lower threshold for ADP secretion in response to LPA. Another possibility is that released 
ADP might activate ADP receptors in LPA-responsive donors better than in non-responsive 
donors. Indeed donor-dependent, inter-individual differences have been described in response to 
ADP (Feng et al., 2001; Michelson et al., 2000; O'Donnell et al., 2001). Although ADP–induced 
(5μM) aggregation was maximal in LPA-non-responders, we can not exclude this possibility 
since only a maximal concentration of ADP was tested and no ADP dose-response curves for 
aggregation in blood were carried out.  
Additionally, the presence of highly active LPP1 in plasma, platelets and blood cells could be 
held responsible for this difference. LPP1 expressed highly in platelets has been shown to 
effectively antagonize LPA-induced platelet activation. LPP1 inhibition has shown to increase 
LPA-induced aggregation 2-3 fold in 6 of 9 donors in gel-filtrated platelets (Smyth et al., 2003). 3 
donors showed no enhanced response in the presence of the LPP1 antagonist (Smyth et al., 2003). 
Thus, if some donors show a higher LPP1 activity or higher LPP1 expression than others, it 
would explain why LPA induces less aggregation in those donors.  
6.2.3. Activation by different LPA species 
Different LPA molecular species have been detected in mox-LDL and atherosclerotic plaques 
(Rother et al., 2003; Zhang et al., 2004). Acyl- LPA (20:4) makes up 15%, alkyl-LPA makes up 
36 % of the total LPA contained in the lipid rich core of atherosclerotic plaques (Rother, 2005). 
Acyl- LPA (20:4) has shown a 6.5- times higher activity than acyl– LPA (16:0) when inducing 
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platelet shape change (Rother, 2005). Our results show that alkyl- LPA (16:0) induced a much 
stronger aggregation in blood than acyl- LPA (16:0) (Fig 5.13). Supporting these findings alkyl-
LPA (16:0) showed an 18-fold higher potency than acyl-LPA (16:0) when inducing platelet shape 
change in PRP (Fig 5.8). Simon et al. demonstrated even a 30-fold higher potency of the alkyl 
species when inducing platelet aggregation of washed platelets (Simon et al., 1984). However, 
observations by Bandoh et al. in sf9- insect cells overexpressing either one of the LPA receptors 
(LPA1, LPA2 or LPA3) show that acyl-LPA had a higher potency than alkyl- LPA (Bandoh et al., 
2000). Moreover, Tokumura et al. published that platelets from 2 out of 30 blood donors didn’t 
react at all to alkyl-LPA, but only in response to acyl-LPA (18:1 as well as 20:4) (Tokumura et 
al., 2002). We did not observe complete non-responders when comparing the two LPA species. 
The higher potency of the alkyl-LPA species for activating platelets and the reported absence of 
alkyl-LPA response in two platelet donors suggest the existence of a yet unknown LPA-receptor 
(Sugiura et al., 1994). 
6.2.4. LPA-induced aggregation in blood and PRP- independence of the 
anticoagulant  
LPA is capable of inducing platelet aggregation in PRP and blood independently of the 
anticoagulant used when comparing hirudin and citrate (Fig 5.14 for whole blood). Hirudin is a 
direct thrombin inhibitor leaving physiological Ca2+ ion levels of 1.1- 1.2 mM.  Citrate lowers 
ionized Ca2+ levels to 40-50μM (Phillips et al., 1997). Citrate anticoagulation and low Ca2+ 
conditions are known to facilitate thromboxane A2 synthesis and granule secretion (Packham et 
al., 1987). In fact some platelet agonists such as ADP and platelet –activating factor are known to 
stimulate thromboxane A2 formation, thromboxane A2–dependent dense granule secretion and the 
second wave of aggregation under low concentrations of extracellular Ca2+ (Packham et al., 1989; 
Siess and Lapetina, 1989). LPA- induced platelet aggregation of washed platelets, PRP and blood 
was independent of platelet cycloogygenase activity, as shown by the lack of inhibition by aspirin 
(Table 5.2a, 5.2b, Table 5.3, Table 5.4, Table 5.5, Fig 5.21, Fig 5.23). This could a reason, why 
LPA-induced platelet aggregation was similar in citrate- and hirudin- anticoagulated PRP and 
blood. 
Concerning the influence of extracellular Ca2+ concentration on LPA-induced platelet 
aggregation using washed platelets there are contradictory results in previous studies. Guegen et 
al showed that Ca2+, 1.3 mM, had an inhibitory effect on LPA-induced aggregation of washed 
platelets. Other studies by Suguira et al and Benton et al showed that the presence of Ca2+ in the 
platelet resuspending buffer increased LPA-induced aggregation of washed platelets ((Eichholtz 
et al., 1993; Gueguen et al., 1999; Sugiura et al., 1994). On the other hand Jalink et al clearly 
illustrated the ability of LPA to form insoluble complexes with Ca2+ with a subsequent decrease 
in the availability of LPA and thus diminishing LPA-induced platelet response (Eichholtz et al., 
1993; Gueguen et al., 1999; Jalink et al., 1995; Sugiura et al., 1994). 
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6.2.5. Synergistic interaction of LPA with serotonin, epinephrine and ADP 
Activation by serotonin of the 5HT2A receptor and activation by ADP of the P2Y1 receptor are 
known to couple to mobilization of calcium from intracellular stores through activation of 
phospholipase C and formation of inositol triphosphate by coupling to the heterotrimeric G 
protein Gq (Leon et al., 1997; Schachter et al., 1996). The P2Y12 receptor and the epinephrine 
receptor couples to adenlylate cyclase via the G protein Gi (Cusack and Hourani, 1982; Hourani 
and Hall, 1994). It has previously been demonstrated that epinephrine and serotonin together are 
able to induce aggregation in isolated platelets (isolated similar as in method 3) (Jin and 
Kunapuli, 1998). Concomitant activation of the same pathway produces no synergistic platelet 
aggregation: Activation of the P2Y1 receptor plus serotonin induced only shape change, also 
activation of the P2Y12 receptor plus stimulation by epinephrine had no synergistic effect (Fig 
5.25) (Jin and Kunapuli, 1998). We observed that LPA synergistically induced platelet 
aggregation of washed platelets with serotonin as well as epinephrine. Interestingly, the 
synergistic platelet aggregation of LPA plus serotonin, but not of LPA plus epinephrine, was 
inhibited by the ADP receptor antagonists indicating a different dependency of the aggregation 
response on released ADP (Fig 5.25). We also observed that LPA synergized with ADP, 
epinephrine, and serotonin in inducing platelet aggregation in blood (Table 5.9 and data not 
shown). We found that LPA does not activate Gi. The synergism inducing platelet aggregation 
may be explained by the activation of different G-protein signalling in platelets: LPA which 
activates G13 synergized with epinephrine and P2Y12 which stimulates Gi, or with serotonin and 
P2Y1 activation stimulating Gq (Fig 6.1).  
To consider the role of Rho-kinase, which is downstream of LPA-induced G12/13 activation, we 
used the Rho-kinase inhibitor Y-27632. Although LPA-induced shape change in whole blood was 
blocked by pre-treatment of platelets with Y-27632, aggregation induced by LPA or by the 
combination of LPA plus ADP was not affected by this drug. These results indicate that Rho-
kinase is not involved in the signalling pathway of LPA that mediates platelet aggregation. Thus 
LPA which does not activate Gi (present study) may only couple to G13. And activation of G13 
triggered by LPA combined with simultaneous activation of Gq or Gi can cause platelet 
aggregation (see Fig 6.1). 
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Fig 6.1 
Mechanism for platelet aggregation 
At least two signal-transduction pathways can synergize with LPA to induce irreversible platelet aggregation. 
Synergism has been demonstrated for the Gq/ Ca2+ pathway and Gi pathway.  
6.2.6. LPA is not a positive feed-back mediator of platelet activation  
LPA formed during platelet aggregation does not seem to be a positive feedback mediator of 
stimulus-induced platelet aggregation. Washed platelets produce about 5 ng LPA/ 109 cells after 
aggregation with thrombin (2 U/ml) that will lead to a calculated maximal concentration of 10 
nM LPA, assuming a complete release of LPA from platelets to the extracellular medium 
(Gerrard and Robinson, 1989). Our results show no significant inhibition of collagen- or 
thrombin–induced aggregation by LPA-receptor antagonists (Table 5.10).  LPA could be too 
weak of an agonist or the released amount of LPA could be too low to enhance aggregation 
induced by a strong stimulus such as thrombin or collagen. Therefore, LPA which is present in 
oxidized LDL and atherosclerotic plaques, seems to be unique in being only pathophysiological, 
but not physiological platelet agonist.  
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6.2.7. Perspective: Preventing LPA-induced platelet aggregation 
The complete independence of platelet aggregation of cylooxygenase-derived prostaglandin 
endoperoxides and thromboxane A2 is not known for other platelet stimuli, except for ADP. 
Although either ADP-receptor antagonist by itself could inhibit LPA-induced aggregation, the 
significance of inhibiting specific LPA-receptors lies in the attempt to influence only 
pathophysiological events without influencing physiological thrombus formation. In the event of 
plaque rupture or platelet activation the local LPA concentration could reach a level slightly 
higher than the circulating plasma level, leading to platelet aggregation. Thus LPA-specific 
receptor antagonists could be a new strategy in the prevention of ischemic events under 
pathophysiological conditions, without the side effects of causing increased bleeding. We suggest 
that ADP-receptor antagonists, which in contrast to aspirin effectively inhibited LPA-induced 
platelet aggregation, might also reduce LPA-triggered thrombus formation in vivo. Based on our 
study we would expect that particularly patients with platelets that are highly sensitive to LPA 
should benefit from this type of antiplatelet drugs. 
6.3. LPA- induced platelet-monocyte adhesion in whole blood 
LPA also stimulated the formation of platelet-monocyte aggregates in whole blood. The dose-
response curve of acyl- LPA was similar to the one for whole blood platelet aggregation.  
However, within the same experiment the extent of platelet aggregation and platelet-monocyte 
aggregate formation often did not correlate suggesting that these two LPA induced-responses are 
regulated differently.  
Concurring with previous studies it was found that LPA-induced platelet-monocyte adhesion was 
P-selectin mediated. P-selectin (GMP 140, PADGEM, CD 62P) is expressed on the surface of 
activated platelets after fusion of α-granules with the plasma membrane of the surface connected 
canalicular system (Stenberg et al., 1985 J of Cell Biol 1985). The P2Y1-antagonist and the 
P2Y12–antagonist separately did not significantly inhibit LPA-induced platelet-monocyte 
aggregate formation in whole blood and P-selectin exposure of washed platelets. Incubation of 
blood with both ADP- receptor antagonists only modestly reduced LPA-stimulated platelet-
monocyte aggregate formation. These results indicate that LPA can stimulate platelet P-selectin 
exposure and subsequent platelet-monocyte aggregate formation through a mechanism 
independent of a synergistic interaction with ADP. Therefore, the mechanism differs from LPA-
induced aggregation in that there is only a minor role of ADP in platelet-monocyte adhesion (Fig 
5.27).  These results are congruent with the data from Zhao et al who found that PAF- and ADP-
induced platelet-monocyte formation could only be inhibited by the combination of P2Y12 
receptor antagonist and dypiridamole (Zhao et al., 2001).  
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Our results with RGDS, a fibrinogen receptor blocking peptide (Arg-Gly-Asp-Ser), that blocked 
aggregation, but not platelet-monocyte aggregate formation, show that these two LPA-induced 
responses are regulated independently of each other (Fig 5.28). These results are in agreement 
with prior studies showing that the fibrinogen receptor does not play a role in platelet-monocyte 
adhesion (Sarma et al., 2002). Platelets respond to LPA either with secretion of ADP from dense 
granules leading to a synergistic aggregation response, or with P-selectin expression and platelet-
monocyte adhesion (Fig 6.2). 
Moreover, platelet-monocyte attachment was Ca2+ dependent and blood donor-independent 
(Table 5.11, Table 5.12), further demonstrating the lack of correlation between the mechanism of 
aggregation and platelet-monocyte formation. Fig 6.2 summarizes the possible mechanism of 
platelet aggregation versus platelet-monocyte attachment. 
 
Fig 6.2 
Schematic Representation of the possible mechanism of platelet-monocyte formation and platelet aggregation 
LPA causes platelet degranulation of dense granules. The ADP contained in dense granules can then amplify LPA-
induced platelet aggregation. Meanwhile LPA also induced P-selectin expression on platelets, which leads to the 
Ca2+ -dependent attachment of platelets to monocytes. 
Interestingly though, in patients with acute myocardial infarction platelet-monocyte adhesion was 
divalent cation-independent, raising the possibility of a new cation-independent mechanism of 
platelet-moncyte adhesion that could be triggered after myocardial injury (Sarma et al., 2002). 
One possibility is that the glycoprotein Ibα (GP Ibα) is involved. GP Ibα was shown recently to 
interact with P-selectin. Platelets expressing the GPIb in a complex with GPIX-V constitute a 
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physiological Ca2+ independent counterreceptor for P-selectin (Romo et al., 1999). However, GP 
Ib-IX-V has not yet been identified on monocytes; therefore, it remains to be seen whether 
binding of P-selectin to GPIbα is an alternative link between platelets and monocytes.  
6.3.1. Perspective: Prevention of LPA-induced platelet-monocyte aggregate 
formation 
The finding that low LPA concentrations stimulate the formation of platelet-monocyte aggregates 
in whole blood is of possible pathophysiological relevance. Oxidatively modified LDL, that 
contains LPA and is elevated in plasma of patients with coronary artery disease, might facilitate 
the formation of platelet-monocyte aggregates(Holvoet and Collen, 1998; Sevanian et al., 1997). 
These are a more sensitive indicator of in vivo platelet activation than platelet P-selectin and have 
been recently recognized as an early marker of acute myocardial infarction (Furman et al., 2001; 
Michelson et al., 2001). Moreover, the adherence of platelets to monocytes stimulates the 
expression of tissue factor on monocytes, promotes fibrin formation and might accelerate 
intravascular thrombosis (Celi et al., 1994). Platelet-monocyte interaction also stimulates the 
synthesis of cytokines such as interleukin-6 that increases the hepatic production of C-reactive 
protein, a risk factor of acute myocardial infarction (Berk et al., 1990; Weyrich et al., 1996). 
The contribution of platelet-monocyte interaction to intra-arterial thrombosis and ischemia-
reperfusion injury causing myocardial infarction is unknown. In cat models of myocardial 
ischemic reperfusion injury it has been shown that disruption of platelet-neutrophil interactions is 
beneficial (Hayward et al., 1999). In baboons, platelets rapidly formed platelet-monocyte 
aggregates after being stimulated in vitro by thrombin and being re-infused (Michelson et al., 
2001). 
Based on the results of this dissertation, conventional anti-platelet therapy, including aspirin, GP 
αIIbβ3 antagonists, and also clopidogrel will not influence LPA- induced platelet–monocyte 
conjugate formation. LPA-stimulated patelet-monocyte adhesion and P-selectin exposure of 
platelets, just as platelet aggregation, was insensitive to inhibition by aspirin. Thus in patients 
with acute coronary syndromes, most of them taking aspirin, platelet-monocyte aggregate 
formation, as early marker of myocardial infarction, will be unaffected.  
The LPA-induced platelet-monocyte adhesion could be of pathological significance in that LPA 
locally released from activated platelets, either present in circulating oxidized LDL, or exposed 
upon plaque disruption by stimulating platelets can attract monocytes to sites of plaque lesions. 
This process might lead to pro-inflammatory feedback mechanisms and progression of 
atherogenesis. LPA-specific receptor antagonists could therefore also be a strategy to attenuate 
inflammation and atherogenesis. 
 
Summary 71
7. Summary 
 
Oxidized LDL and platelets play a central role in the pathogenesis of atherosclerosis and 
ischemic cardiovascular diseases. Lysophosphatidic acid (LPA) is a thrombogenic substance that 
accumulates in mildly-oxidized LDL and in human atherosclerotic lesions, and is responsible for 
the initial platelet activation, shape change, induced by mildly-oxidized LDL and extracts of 
lipid-rich atherosclerotic plaques (Siess et al., 1999 Proc Natl Acad Sci USA 1999). LPA directly 
induced platelet shape change in blood and platelet-rich plasma (PRP) obtained from all blood 
donors. Albumin was one of the main inhibiting factors of platelet shape change in plasma. 
Interestingly LPA, at concentrations slightly above plasma levels, induced platelet shape change 
and aggregation in blood. 1-alkyl-LPA (16:0) was almost 20-fold more potent than 1-acyl-LPA 
(16:0). LPA-stimulated platelet aggregation in blood and PRP was donor-dependent.  
LPA-induced aggregation in blood could be completely blocked by the ADP- scavenging 
enzyme, apyrase, and antagonists of the platelet ADP-receptors P2Y1 and P2Y12. These 
substances also inhibited LPA-induced aggregation of platelet-rich plasma, and aggregation and 
serotonin secretion of washed platelets. These results indicate a central role for ADP-mediated 
P2Y1 and P2Y12 receptor activation in supporting LPA-induced platelet aggregation and show 
that LPA synergistically with ADP induces platelet aggregation in blood. Thus antagonists of 
platelet P2Y1 and P2Y12 receptors, especially in donors highly sensitive to LPA, might be useful 
in preventing LPA-elicited thrombus formation in patients with cardiovascular diseases. 
The mechanism of LPA plus ADP-induced aggregation was independent of the Rho/Rho kinase 
pathway which mediated LPA-induced platelet shape change in blood. LPA, activating G13, but 
not Gi or Gq synergized also with epinephrine, activating Gi, and serotonin, activating Gq, in 
amplifying LPA-induced platelet aggregation in washed platelets. LPA/serotonin-induced 
aggregation was blocked by either ADP-receptor antagonist whereas synergistic aggregation 
induced by LPA/epinephrine was independent from ADP-receptor antagonists. The latter results 
demonstrate an additional mechanism for aggregation independent of P2Y1 and P2Y12. Most 
surprising, LPA-induced platelet aggregation was insensitive to inhibition by aspirin.  
LPA at low concentrations, starting slightly above plasma level, was also capable of eliciting 
platelet-monocyte conjugate formation. LPA-induced platelet-monocyte formation was 
independent of the blood donor. ADP mediated P2Y1 and P2Y12 receptor activation played only a 
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minor role.  Platelet-monocyte aggregate formation stimulated by LPA was P-selectin-mediated 
and insensitive to inhibition by aspirin.  
Pathophysiolocical events such as sudden plaque rupture or progressive enrichment of circulating 
oxidized LDL at critical sites of turbulent flow might lead to higher local blood concentration of 
LPA. This can induce platelet shape change, platelet aggregation and platelet-monocyte 
formation at atherosclerotic sites. LPA receptor antagonists could be of possible benefit not only 
preventing arterial thrombosis, but also retarding vascular inflammation in patients with 
cardiovascular disease. 
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8. Zusammenfassung 
Oxidiertes LDL und Thrombozyten spielen eine zentrale Rolle in der Entstehung von  
Atherosklerose und von ischämischen kardiovaskulären Ereignissen. In  milde oxidiertem LDL 
und in atherosklerotischen Läsionen akkumuliert Lysophosphatidsäure (LPA), welche als 
thrombogene Substanz, die initiale Thrombozytenaktivierung, den Gestaltwandel, verursachen 
kann. Es wurde gezeigt, dass milde oxidiertes LDL und Extraktionen aus lipid-reichen 
atherosklerotischen Plaques der Gestaltwandel (shape change) der Thromozyten induzieren kann 
(Siess et al., 1999 Proc Natl Acad Sci USA 1999). Gleichermaβen kann LPA kann den 
Gestaltwandel von Thrombozyten im Blut und in Plättchen-reichem Plasma (PRP) induzieren, 
wobei sich Albumin als einer der Hauptinhibitoren in PRP zeigte. Bemerkenswerterweise konnte 
LPA schon ab Konzentrationen gering über der LPA Plasma Konzentration den Gestaltwandel 
und die Aggregation von Thrombozyten induzieren. Als besonders potent  gilt 1- Alkyl-LPA 
(16:0), welches in 20-fach schwächerer Konzentration als 1-Acyl- LPA (16:0) den Gestaltwandel 
in PRP und die Aggregation im Blut verursachte. Die LPA-stimulierte Thrombozyten- 
Aggregation im Blut und im PRP waren interessanterweise abhängig von dem jeweiligen 
Blutspender.   
Die LPA-induzierte Aggregation im Blut konnte durch das ADP- hydrolisierende Enzym, 
Apyrase, die Inhibition von den ADP- Rezeptoren P2Y1 und P2Y12, komplett gehemmt werden. 
Ebenfalls konnte die LPA-induzierte Aggregation in Plättchen-reichem Plasma, wie auch die 
Aggregation und die Serotonin Sekretion in isolierten Thrombozyten durch Apyrase und die 
ADP-Rezeptoren komplett gehemmt werden. Diese Ergebnisse unterstreichen die zentrale Rolle 
der ADP-Rezeptor (P2Y1 und P2Y12) vermittelten Aktivierung, in der durch LPA induzierten 
Thromboztenaktivierung.  Gleichzeitig zeigt dieser Synergismus, dass LPA zusammen mit ADP 
die Thrombozyten Aktivierung im Blut unterhält. Aus diesem Grund sind Antagonisten des  P2Y1 
and des P2Y12 Rezeptors, besonders bei Blutspendern, die hochsensibel auf LPA reagieren, 
sinnvoll in der Prävention von LPA-induzierter Thrombus-Formation in Patienten mit 
kardiovaskulären Erkrankungen.  
Im Gegensatz zu dem LPA-vermittelten Gestaltwandel im Blut, war die LPA- plus ADP- 
vermittelte Aggregation im Blut Rho/Rho kinase unabhängig. LPA welches  G13, aber nicht Gi 
oder Gq aktiviert, konnte zusammen mit Epinephrine, welches Gi aktiviert, und mit Serotonin, 
welches Gq aktiviert, in Synergismus treten und die LPA-induzierte Aggregation in gewaschenen 
Thrombozyten potenzieren.  Die LPA/Serotonin-induzierte Aggregation konnte durch den 
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jeweiligen ADP- Rezeptor Antagonisten gehemmt werden, hingegen war die synergistisch 
induzierte Aggregation durch LPA/ Epinephrine unabhängig von beiden ADP- Rezeptor 
Antagonisten. Die letzteren Ergebnisse suggerieren, das ein zusätzlicher Mechanismus für die 
LPA-induzierte Aggregation, unabhängig von P2Y1 und P2Y12, existiert. Überraschenderweise 
konnte die LPA induzierte Thrombozyten Aggregation nicht durch Aspirin gehemmt werden.  
Niedrige LPA- Konzentrationen, gering über der Plasma Konzentration, lösten auch die 
Formation von Thrombozyten- Monozyten- Konjugaten aus. Die LPA- induzierte Thrombozyten- 
Monozyten- Formation war unabhängig von dem jeweiligen Blutspender. Im Vergleich zur LPA-
induzierten Thrombozyten Aggregation, spielte die ADP- vermittelte Aktivierung des P2Y1 und 
des P2Y12 Rezeptors nur eine untergeordnete Rolle. Die Thrombozyten- Monozyten- Formation 
war P- Selektin- vermittelt und war auch durch Aspirin nicht hemmbar. 
Pathophysiologische Ereignisse, wie die Ruptur eines atherosklerotischen Plaques oder die 
Anreicherung von zirkulierendem oxidiertem LDL an kritischen Stellen, z.B. Gefäßbifurkationen, 
mit turbulenten Strömungsverhältnissen kann zu lokal erhöhten Blutkonzentrationen von LPA 
führen. Dies kann zur Thrombozytenaktivierung in Form von Gestaltwandel, Aggregation, und 
Thrombozyten- Monozyten Formation an Atherosklerotischen Plaques führen. LPA- Rezeptor 
Antagonisten können dabei eine maβgebliche Rolle in der Prävention, nicht nur von arteriell 
thrombotischen Ereignissen, sondern auch von vaskulär entzündlichen Prozessen in Patienten mit 
kardiovaskulären Ereignissen, darstellen.  
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